

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

A29

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07D 239/70, A61K 31/505, C07D 487/04, 513/04, 498/04, 495/04, 513/14, 495/14, 491/048, A61K 31/495 // (C07D 487/04, 239:00, 209:00) (C07D 513/04, 277:00, 239:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/19970 (43) International Publication Date: 27 July 1995 (27.07.95)</p>
<p>(21) International Application Number: PCT/US95/00911 (22) International Filing Date: 23 January 1995 (23.01.95) (30) Priority Data: 186,735 25 January 1994 (25.01.94) US 186,745 25 January 1994 (25.01.94) US 358,352 23 December 1994 (23.12.94) US (71) Applicant: WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors: BRIDGES, Alexander, James; 3301 Textile Road, Saline, MI 48176 (US). DENNY, William, Alexander; 165 Gossamer Drive, Pakuranga, Auckland (NZ). FRY, David; 3647 Textile Road, Ypsilanti, MI 48197 (US). KRAKER, Alan; 2515 Prairie Street, Ann Arbor, MI 48105 (US). MEYER, Robert; 5870 Warren Road, Ann Arbor, MI 48105 (US). REWCASTLE, Gordon, William; 107 Grande Vue Road, Manurewa, Auckland (NZ). THOMPSON, Andrew, Mark; 2/13 Raihiri Road, Mount Eden, Auckland (NZ). SHOWALTER, Howard, Daniel, Hollis; 3578 Lamplighter Drive, Ann Arbor, MI 48103 (US).</p>	<p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al. (81) Designated States: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY</p> <p>(57) Abstract</p> <p>Epidermal growth-factor inhibitors of formula (I), wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle; A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen. X = O, S, NH or NR⁹, such that R⁹ = lower alkyl, OH, NH₂, lower alkoxy or lower monoalkylamino m = 0-3, and Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinoliny, isoquinoliny and quinazolinyl.</p> <div data-bbox="763 1176 1055 1344"> </div> <p>(I)</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 95/19970

PCT/US95/00911

TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY

Technical Field

5 The present invention relates to tricyclic heteroaromatic compounds which inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzymic activity.

Background Art

10 Cancer is generally a disease of the intracellular signalling system, or signal transduction mechanism. Cells receive instructions from many extracellular sources, instructing them to either proliferate or not to proliferate. The purpose of the
15 signal transduction system is to receive these and other signals at the cell surface, get them into the cell, and then pass the signals on to the nucleus, the cytoskeleton, and transport and protein synthesis machinery. The most common cause of cancer is a se-
20 ries of defects, either in these proteins, when they are mutated, or in the regulation of the quantity of

WO 95/19970

PCT/US95/00911

-2-

the protein in the cell such that it is over or under produced. Most often, there are key lesions in the cell which lead to a constitutive state whereby the cell nucleus receives a signal to proliferate, when this signal is not actually present. This can occur through a variety of mechanisms. Sometimes the cell may start to produce an authentic growth factor for its own receptors when it should not, the so-called autocrine loop mechanism. Mutations to the cell surface receptors, which usually signal into the cell by means of tyrosine kinases, can lead to activation of the kinase in the absence of ligand, and passing of a signal which is not really there. Alternatively, many surface kinases can be overexpressed on the cell surface leading to an inappropriately strong response to a weak signal. There are many levels inside the cell at which mutation or overexpression can lead to the same spurious signal arising in the cell, and there are many other kinds of signalling defect involved in cancer. This invention touches upon cancers which are driven by the three mechanisms just described, and which involve cell surface receptors of the epidermal growth factor receptor tyrosine kinase family (EGFR). This family consists of the EGF receptor (also known as Erb-B1), the Erb-B2 receptor, and its constitutively active oncoprotein mutant Neu, the Erb-B3 receptor and the Erb-B4 receptor. Additionally, other biological processes driven through members of the EGF family of receptors can also be treated by compounds of the invention described below.

The EGFR has as its two most important ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha (TGFalpha). The receptors appear

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-3-

to have only minor functions in adult humans, but are apparently implicated in the disease process of a large portion of all cancers, especially colon and breast cancer. The closely related Erb-B2 Erb-B3 and Erb-B4 receptors have a family of Heregulins as their major ligands, and receptor overexpression and mutation have been unequivocally demonstrated as the major risk factor in poor prognosis breast cancer. Additionally, it has been demonstrated that all four of the members of this family of receptors can form heterodimeric signalling complexes with other members of the family, and that this can lead to synergistic transforming capacity if more than one member of the family is overexpressed in a malignancy. Overexpression of more than one family member has been shown to be relatively common in human malignancies.

The proliferative skin disease psoriasis has no good cure at present. It is often treated by anti-cancer agents such as methotrexate, which have very serious side effects, and which are not very effective at the toxicity-limited doses which have to be used. It is believed that TGF α is the major growth factor overproduced in psoriasis, since 50% of transgenic mice which overexpress TGF α develop psoriasis. This suggests that a good inhibitor of EGFR signalling could be used as an antipsoriatic agent, preferably, but not necessarily, by topical dosing.

EGF is a potent mitogen for renal tubule cells. Fourfold increases in both EGF urinary secretion and EGF mRNA have been noted in mice with early stage streptozocin-induced diabetes. In addition

WO 95/19970

PCT/US95/00911

-4-

increased expression of the EGFR has been noted in patients with proliferative glomerulonephritis (Roychaudhury et al. *Pathology* 1993, 25, 327). The compounds of the current invention should be useful in treating both proliferative glomerulonephritis and diabetes-induced renal disease.

Chronic pancreatitis in patients has been reported to correlate with large increases in expression for both EGFR and TGF alpha. (Korc et al. *Gut* 1994, 35, 1468). In patients showing a more severe form of the disease, typified by an enlargement of the head of the pancreas, there was also shown to be overexpression of the erb-B2 receptor (Friess et al. *Ann. Surg.* 1994, 220, 183). The compounds of the current invention should prove useful in the treatment of pancreatitis.

In the processes of blastocyte maturation, blastocyte implantation into the uterine endometrium, and other periimplantation events, uterine tissues produce EGF and TGF alpha (Taga *Nippon Sanka Fujinka Gakkai Zasshi* 1992, 44, 939), have elevated levels of EGFR (Brown et al. *Endocrinology*, 1989, 124, 2882), and may well be induced to produce heparin-binding EGF by the proximity of the developing, but not arrested, blastocyte (Das et al. *Development* 1994, 120, 1071). In turn the blastocyte has quite a high level of TGF alpha and EGFR expression (Adamson *Mol. Reprod. Dev.* 1990, 27, 16). Surgical removal of the submandibular glands, the major site of EGF secretion in the body, and treatment with anti-EGFR monoclonal antibodies both greatly reduce fertility in mice (Tsutsumi et al. *J. Endocrinology* 1993, 138, 437), by reducing success-

WO 95/19970

PCT/US95/00911

-5-

ful blastocyte implantation. Therefore, compounds of the current invention should prove to have useful contraceptive properties.

5 PCT patent application Nos. WO92/07844 published May 14, 1992 and WO92/14716 published September 3, 1992 describe 2,4-diaminoquinazoline as potentiators of chemotherapeutic agents in the treatment of cancer.

10 PCT published application No. WO92/20642 published November 26, 1992 discloses bismono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase.

15 It is an object of the present invention to inhibit the mitogenic effects of epidermal growth factor utilizing an effective amount of tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives.

20 It is another object of the present invention to describe tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives, as inhibitors of the EGF, Erb-B2 and Erb-B4 receptor tyrosine kinases.

25 It is yet another object of the present invention to describe tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives, that are useful at low dosages as inhibitors of EGF-induced mitogenesis. This therefore leads to a further object of compounds having extremely low cytotoxicity.

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-6-

It is a further object of the present invention to describe tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives, that are useful in suppressing tumors, especially
5 breast cancers, where mitogenesis is heavily driven by EGFR family members.

It is another object of the present invention to describe tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives,
10 that have utility as chronic therapy as inhibitors of EGF-induced responses.

It is another object of the current invention to describe tricyclic pyrimidine derivatives, in particular fused heterocyclic pyrimidine derivatives,
15 that have utility as therapeutic agents against proliferative overgrowth diseases, including but not limited to, synovial pannus invasion in arthritis, vascular restenosis and angiogenesis. Additional utility of these materials is for pancreatitis and
20 kidney disease as well as contraception.


Summary of the Invention

Described is a method to inhibit epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of
25 the following formula:

WO 95/19970

PCT/US95/00911

-7-



wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricy-
 cle, or 2) one of Y and Z is C=C, C=N whereupon the
 5 other one of Y or Z is simply a bond between the two
 aromatic rings, then the ring structure is a nonlinear
 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or
 S, whereupon the other one of Y or Z is simply a bond
 between the two aromatic rings, then the ring struc-
 10 ture is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to
 two of them can be nitrogen, whereupon the remaining
 atoms must be carbon, or any two contiguous positions
 in A-E can be a single heteroatom, N, O or S, forming
 15 a five membered fused ring, in which case one of the
 two remaining atoms must be carbon, and the other can
 be either carbon or nitrogen, except that the case
 where A and B taken together, and D and E taken sepa-
 rately are all three nitrogen atoms;

20 X = O, S, NH or NR⁹, such that R⁹ = lower
 alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4
 carbon atoms) or lower monoalkylamino (1-4 carbon
 atoms);

R¹ = H or lower alkyl;
 25 n = 0, 1 or 2;

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-8-

if $n = 2$, R^1 can be independently H or lower alkyl on either linking carbon atom, and both R and S stereocentres on either linker are included;

R^2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; $-O-C(O)-R$), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; $-C(O)R$), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxy-carbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R^2 taken together can form a carbocyclic ring of 5-7 members; and

$m = 0-3$, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R^3 , R^4 , R^5 and R^6 are independently, not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato ($-OC(O)OR$)

WO 95/19970

PCT/US95/00911

-9-

where R is alkyl of from 1-4 carbon atoms or cyclo-alkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by
5 mono or di-lower alkyl (1-4 carbon atoms) or cyclo-alkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thio-cycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N- and/or N'- mono- or
10 di lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, N- and/or O- mono- or di lower alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused
15 pyrrolidine, tetrahydrofuranyl, piperidinyl, piper-azinyl, morpholino or thiomorpholino ring;

R' and R^a can be independently as appropriate, lone pairs of electrons, H, or lower alkyl;

any lower alkyl group substituent on any of
20 the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkyl-amino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

25 if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms),
30 amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create

WO 95/19970

PCT/US95/00911

-10-

chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

5 The invention pertains to the compounds, per se:

 with the proviso that the ring containing A-E is aromatic;

 and with the proviso that if A and B taken
10 together and E are nitrogen, and if neither Y nor Z is a heteroatom, and if $X = NH$, and $n = 1$, and $R^1 = H$ and $Ar = Ph$, then one of the imidazole nitrogen atoms must have a substituent from the R^3-R^6 group other than lone pair or hydrogen;

15 and with the proviso that if A-E are carbon, and Y is a bond, and Z is sulfur, and $X = NH$, and $n = 0$, then Ar cannot be unsubstituted phenyl, unsubstituted or substituted pyridyl or unsubstituted or substituted pyrimidyl.

20 Preferably, the compounds are subject to additional provisos:

 with the proviso that if A-E are carbon, Y and Z cannot be both carbon or one ethylidene and the other a bond, unless at least one of R^3-R^6 is not hydrogen;
25

 with the proviso that if A-E are carbon one of Y and Z cannot be nitrogen, substituted with hydrogen, and the other a bond.

WO 95/19970

PCT/US95/00911

-11-

Brief Description Of The Drawings

FIGURE 1 is an effect of Example 1 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

5 FIGURE 2 is an effect of Examples 6 and 17 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

10 FIGURE 3 is an effect of Example 8 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

FIGURE 4 is an effect of Example 10 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

15 FIGURE 5 is an effect of Example 15 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

FIGURE 6 is an effect of Example 25 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

20 FIGURE 7 is an effect of Example 28 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma;

25 FIGURE 8 is an effect of Example 29 on EGF receptor autophosphorylation in A431 human epidermoid carcinoma; and

WO 95/19970


PCT/US95/00911

-12-

FIGURE 9 is an effect of Examples 6 and 17 on soft agar clone formation of MDA-MB-468 human breast carcinoma.

Description of Preferred Embodiments

5 Nomenclature and Numbering as used Herein



Nomenclature. All tricycles containing a benzene ring fused directly to the pyrimidine ring have been named as quinazoline derivatives. All other tricycles are named as pyrimidine derivatives, either fused to a bicyclic nucleus such as indole or benzo-
 10 thiophene, or to two separate monocyclic heterocycles such as pyridothiophene. In such cases the first ring given is always the one distal to the pyrimidine ring.

Ring fusion numbers. For quinazoline derivatives the quinazoline nucleus is lettered counter-clockwise with the N1-C2 bond being a, and the three possible ring fusion positions being f, g and h. The C-ring is numbered 1-5/6 from its highest atomic weight heteroatom, with the ring fusion numbering
 15 being decided by the numbered bridgehead atom which first meets the counterclockwise flow of the quinazoline lettering.
 20

WO 95/19970

PCT/US95/00911

-13-

For systems with three fused heteroaromatic rings, the pyrimidine ring (A) is always chosen as the root system and is d-fused to the B-ring lettering in a clockwise direction. The central B-ring is numbered 1-5/6, starting at the heteroatom, and going first via the B/C ring junction and then the B/A ring junction. It can be numbered either clockwise, when the heteroatom is at the bottom, or counterclockwise, when the heteroatom is at the top, (as is illustrated above), and the ring fusion numbering is decided by the numbered bridgehead atom which first meets the clockwise flow of the pyrimidine lettering. The C-ring is numbered 1'-5'/6' from the highest priority heteroatom, towards lower priority heteroatoms if present, and if there are no other heteroatoms, in the direction which gives the lowest numbering to the ring junction. The first C-ring fusion number is that of the bridgehead atom which has the lowest numbering in the B-ring numbering system. In the first set of parentheses the C-ring numbers of the B/C bridgehead atoms are given, followed after the colon by the B-ring numbers for the same atoms. The second set of parentheses contain the B-ring numbers for the A/B-bridgehead atoms, followed after the dash by the shared bond in the A-ring lettering system. Thus, the example above illustrates a [5',4':2,3] [5,6-d] tricyclic system.


Substituent Numbering. In all of the examples, the numbering is taken from the bottom nitrogen of the pyrimidine A ring as 1, and then all nonbridgehead atoms are counted consecutively in a counterclockwise direction from that point, as illustrated above for a 6,6,6-system by the bolded numbers.

WO 95/19970


PCT/US95/00911

-14-

1. A preferred form of the invention has $n = 0$, A-E, Y & Z being carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen. A suitable ring structure is:



5 2. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, along with Y and Z, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone
10 pair of electrons where appropriate. A suitable ring structure is:




3. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as sulfur, the remaining pair both being
15 carbon, along with Y and Z, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate.

WO 95/19970

PCT/US95/00911


-15-

4. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, along with Y and Z, $X = \text{NH}$, Ar a benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen or optionally lower alkyl if on nitrogen. A suitable ring structure is:



5. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, Y and Z both carbon, $X = \text{NH}$, Ar a benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen or a lone pair of electrons where appropriate.

6. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, Y and Z both carbon, $X = \text{NH}$, Ar a benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:



WO 95/19970

PCT/US95/00911

-16-

7. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together, and E as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or optionally lower alkyl if on nitrogen. or a lone pair of electrons where appropriate.

8. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.


9. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

10. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate. A suitable ring structure is:

WO 95/19970

PCT/US95/00911

-17-



11. Another preferred form of the invention has $n = 0$, A & B taken together, with D & E taken separately as nitrogen, Y and Z both carbon, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen. or a lone pair of electrons where appropriate.

12. Another preferred form of the invention has $n = 0$ or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

13. Another preferred form of the invention has $n = 0$, with any two of A, B, D or E as nitrogen, the remaining two being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.


14. Another preferred form of the invention has $n = 0$, A-E, and one of Y and Z being carbon, the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of elec-

WO 95/19970


PCT/US95/00911

-18-

trons where appropriate. A suitable ring structure is:



15. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate. A suitable structure is:



16. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate.

17. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken


WO 95/19970

PCT/US95/00911

-19-

together as nitrogen, the remaining pair both being carbon, along with one of Y and Z, the other being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, or optionally lower alkyl
5 if on nitrogen in the pyrrole ring, or a lone pair of electrons where appropriate.

18. Another preferred form of the invention has n = 0 or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y and Z being carbon the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:



19. Another preferred form of the invention has n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y and Z being carbon the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

20. Another preferred form of the invention has n = 0 or 1, A & B taken together, and E as nitrogen, one of Y and Z being carbon the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and
25

WO 95/19970

PCT/US95/00911

-20-

R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen or a lone pair of electrons where appropriate.

21. Another preferred form of the invention has n = 0 or 1, A & B taken together as oxygen, and D
5 as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y and Z being carbon the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

10 22. Another preferred form of the invention has n = 0 or 1, A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, one of Y and Z being carbon the other
15 nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

23. Another preferred form of the invention has n = 0 or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one
20 of Y and Z being carbon the other nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.


24. Another preferred form of the invention has n = 0 or 1, with one of A, B, D or E as nitrogen,
25 the remaining three being carbon, along with one of Y and Z, the other being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A suitable
30 ring structure is:

SUBSTITUTE SHEET (RULE 26)

WO 95/19970


PCT/US95/00911

-21-



25. Another preferred form of the invention has $n = 0$, with any two of A, B, D or E as nitrogen, the remaining two being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate.

26. A preferred form of the invention has $n = 0$, A-E carbon, Y and Z nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:




27. Another preferred form of the invention has $n = 0$ or 1, A-E being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen. A suitable ring structure is:

WO 95/19970

PCT/US95/00911

-22-



28. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

29. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

30. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen.

31. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being ethylidene, X = NH, Ar

WO 95/19970


PCT/US95/00911

-23-

a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

32. Another preferred form of the invention has n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

33. Another preferred form of the invention has n = 0, A & B taken together, and E as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen or a lone pair of electrons where appropriate. A suitable ring structure is:



34. Another preferred form of the invention has n = 0 or 1, A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.


SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-24-

35. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, one of Y & Z being ethylidene, $X = NH$, Ar
5 a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate. A suitable ring structure is:



36. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen,
10 one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

37. Another preferred form of the invention has $n = 0$ or 1 , with one of A, B, D or E as nitrogen,
15 the remaining three being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate.

38. Another preferred form of the invention has $n = 0$, with any two of A, B, D or E as nitrogen,
20 the remaining two being carbon, one of Y & Z being


WO 95/19970

PCT/US95/00911

-25-

ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

39. Another preferred form of the invention has n = 0 or 1, A-E being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:



40. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

41. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

42. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being

WO 95/19970

PCT/US95/00911

-26-


carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate or optionally lower alkyl if on nitrogen.

5 43. Another preferred form of the invention has n = 0 or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

10

 44. Another preferred form of the invention has n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:

15



 45. Another preferred form of the invention has n = 0, A & B taken together, and E as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen. or a lone pair of electrons where appropriate.

20

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-27-

46. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being sulfur, $X = NH$, Ar a
5 benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

47. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and D
10 as nitrogen, or D & E taken together as sulfur and B as nitrogen, one of Y & Z being sulfur, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

48. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one
15 of Y & Z being sulfur, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.
20

49. Another preferred form of the invention has $n = 0$ or 1 , with one of A, B, D or E as nitrogen, the remaining three being carbon, one of Y & Z being
25 sulfur, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate.

50. Another preferred form of the invention has $n = 0$ or 1 , A-E being carbon, one of Y & Z being
nitrogen, $X = NH$, Ar a benzene ring, optionally sub-

WO 95/19970

PCT/US95/00911

-28-

stituted, and R^5 - R^8 hydrogen, or optionally lower alkyl if on nitrogen.

51. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate, or optionally lower alkyl if on nitrogen.

52. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being nitrogen, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate, or optionally lower alkyl if on nitrogen.


53. Another preferred form of the invention has, $n = 0$ or 1 , with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or optionally lower alkyl if on nitrogen.

54. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate, or optionally lower alkyl if on nitrogen. A suitable ring structure is:

WO 95/19970

PCT/US95/00911

-29-



55. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons where appropriate, or optionally lower alkyl if on nitrogen.

56. Another preferred form of the invention has $n = 0$, A & B taken together, and E as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or optionally lower alkyl if on nitrogen or a lone pair of electrons where appropriate.

57. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

58. Another preferred form of the invention has $n = 0$ or 1 , A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B

WO 95/19970

PCT/US95/00911


-30-

as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

5 59. Another preferred form of the invention has n = 0 or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

10 60. Another preferred form of the invention has n = 0 or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

15 61. Another preferred form of the invention has n = 0 or 1, A-E being carbon, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A suitable ring structure is:



20 62. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken

WO 95/19970

PCT/US95/00911

-31-

together as oxygen, the remaining pair both being carbon, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

5 63. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen
10 or a lone pair of electrons where appropriate.

 64. Another preferred form of the invention has, n = 0 or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen
15 or a lone pair of electrons where appropriate or optionally lower alkyl if on nitrogen.


 65. Another preferred form of the invention has n = 0 or 1, A & B taken together as oxygen, and E
20 as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate.

 66. Another preferred form of the invention
25 has n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons where appropriate. A
30 suitable ring structure is:

WO 95/19970

PCT/US95/00911

-32-



67. Another preferred form of the invention has $n = 0$, A & B taken together, and E as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or optionally lower alkyl if on nitrogen or a lone pair where appropriate.

68. Another preferred form of the invention has $n = 0$ or 1, A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

69. Another preferred form of the invention has $n = 0$ or 1, A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

70. Another preferred form of the invention has $n = 0$ or 1, A & B taken together, and D as nitro-

WO 95/19970

PCT/US95/00911

-33-

gen, or D & E taken together, and B as nitrogen, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

5 71. Another preferred form of the invention has n = 0 or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, one of Y & Z being oxygen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons
10 where appropriate.

Most Preferred Forms of the Invention

1. A most preferred form of the invention is one where A-E, Y and Z are all carbon, n = 0, X = NH, Ar is phenyl, R² is meta-bromo, m = 1, and R³-R⁸ are
15 all hydrogen.

2. A most preferred form of the invention is one where A-E, Y and Z are all carbon, n = 1, X = NH, Ar is phenyl, R¹ is [R]-CH₃, and R²-R⁸ are all hydrogen.

20 3. A most preferred form of the invention is one where A and B are carbon, D and E taken together are nitrogen, Y and Z are carbon, n = 0, X = NH, Ar is phenyl, R² is meta-bromo, m = 1, and R⁴-R⁸ are all hydrogen.

25 4. A most preferred form of the invention is one where A and B taken together are sulfur, E is nitrogen, D, Y and Z are carbon, n = 0, X = NH, Ar is

WO 95/19970

PCT/US95/00911

-34-

phenyl, R^2 is meta-bromo, $m = 1$, and R^4 and R^6 - R^8 are all hydrogen.

5 5. A most preferred form of the invention is one where A and B taken together are oxygen, E is nitrogen, D, Y and Z are carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^4 and R^6 - R^8 are all hydrogen.

10 6. A most preferred form of the invention is one where A and B taken together are nitrogen, E is nitrogen, D, Y and Z are carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^4 and R^6 - R^8 are all hydrogen.

15 7. A most preferred form of the invention is one where A and B taken together are nitrogen, D and E taken separately are nitrogen, Y and Z are carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^6 - R^8 are all hydrogen.

20 8. A most preferred form of the invention is one where A and B taken together are nitrogen, E is nitrogen, Y and Z are carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^4 , R^7 and R^8 are hydrogen and R^6 is methyl.

25 9. A most preferred form of the invention is one where A and B taken together are nitrogen, E is nitrogen, Y and Z are carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^4 , R^7 and R^8 are hydrogen and R^5 is methyl.

WO 95/19970

PCT/US95/00911

-35-

10. A most preferred form of the invention is one where A and E are nitrogen, B, D, Y and Z are all carbon, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^3 - R^8 are all hydrogen.

5 11. A most preferred form of the invention is one where A and B taken together are nitrogen, E is nitrogen, Z is ethylidene, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^4 and R^6 - R^8 are all hydrogen.

10 12. A most preferred form of the invention is one where A-E, are all carbon, Z is sulfur, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^3 - R^6 are all hydrogen.

15 13. A most preferred form of the invention is one where A-E, are all carbon, Z is sulfur, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, R^5 is nitro R^3 , R^4 and R^6 are all hydrogen.

20 14. A most preferred form of the invention is one where A-E, are all carbon, Z is sulfur, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, R^5 is amino R^3 , R^4 and R^6 are all hydrogen.

25 15. A most preferred form of the invention is one where A-E, are all carbon, Z is sulfur, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, R^6 is methoxy and R^3 - R^5 are all hydrogen.

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-36-

16. A most preferred form of the invention is one where A is nitrogen, D and E taken together, and Z are sulfur and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^3 is hydrogen.

5 17. A most preferred form of the invention is one where A-E, are all carbon, Z is nitrogen, and Y a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^3 - R^6 and R^8 are all hydrogen.

10 18. A most preferred form of the invention is one where A-E, are all carbon, Y is nitrogen, and Z a C-C bond, $n = 0$, $X = NH$, Ar is phenyl, R^2 is meta-bromo, $m = 1$, and R^3 - R^6 and R^8 are all hydrogen.

15 The compounds of the present invention are prepared according to a number of alternative reaction sequences.

20 It is to be appreciated that in the tricyclic structure of Formula I, the ring having A-E is aromatic. By "aromatic" is meant that all members of the ring share electrons and there is a resonance among the members of the ring.

**Preparative Routes to
Compounds of the Invention**

Scheme 1 for Preferred Group 1

25 Condensation of commercially available 3-amino-2-naphthoic acid with formamide gives the benzoquinazoline nucleus. (DMF is dimethyl formamide). Conversion of the carbonyl to halide is followed by displacement with the appropriate amine side chain.

WO 95/19970

PCT/US95/00911

-37-

Representative examples of compounds that can be made by this route are given in the table below.

Scheme 2 for Preferred Group 4 [3,2-g] Isomer

Nitration of methyl 5-methyl-2-nitrobenzoate, and isomer separation gives the 2,4-dinitrobenzoate ester. This is converted to the corresponding benzamide with methanolic ammonia, and both the amide nitrogen and the benzylic methyl are condensed with DMF di-t-butoxy acetal. On Raney Nickel reduction of both nitro groups to amines both the pyrrole and pyrimidone rings spontaneously cyclize to give the desired pyrrolo[3,2-g]quinazolone. Conversion on to the chloride with POCl₃ is followed by displacement of the chlorine with the desired amine.

15 Scheme 3 - Route for Preferred Group 5 [4,5 -g] Isomer

For the [4,5-g] isomer 7-chloroquinazol-4-one is nitrated at the 6-position by methods familiar to one skilled in the art. The activated 7-halide is then displaced by methoxide, the methyl ether is cleaved, the nitro group is reduced to amino, and the oxazole ring is cyclized on with formic acid. Phosphorus pentasulfide followed by methyl iodide activates the 4-position, and the synthesis is completed by displacement of the 4-methylthio group by an appropriate amine.

WO 95/19970

PCT/US95/00911

-38-

Scheme 4 - Route for Preferred Group 5 [5,4 -g] Isomer

For the [5,4-g] isomer the chlorine atom of the known 5-chloro-2,4-dinitrobenzamide is displaced with KOH, and the two nitro groups are then
5 catalytically reduced to the diaminohydroxybenzamide. Treatment of this with excess orthoformate cyclizes both the oxazole and pyrimidone rings simultaneously, to give the desired tricyclic nucleus. Activation of the 4-oxo group with POCl₃ or other suitable
10 chlorinating agent followed by displacement with the appropriate amine gives the desired compounds.

Scheme 5 - Route for Preferred Group 6 [4,5 -g] Isomer

For the [4,5-g] isomer 7-chloroquinazol-4-one is nitrated at the 6-position by methods familiar
15 to one skilled in the art. The activated 7-halide is then displaced by methiolate ion, and the resultant thiomethyl ether is cleaved under the reaction conditions to give the corresponding thiol. The nitro group is reduced by a noncatalytic method, such as
20 treatment with hydrosulfide ion or Zn/AcOH, and the thiazole ring is cyclized on with orthoformate. Phosphorus pentasulfide followed by methyl iodide activates the 4-position, and the synthesis is completed by displacement of the 4-methylthio group by
25 an appropriate amine.

Scheme 6 - Route for Preferred Group 6 [5,4 -g] Isomer

For the [5,4-g] isomer the chlorine atom of the known 5-chloro-2,4-dinitrobenzamide is displaced with NaSH, and the 4-nitro group is concomitantly
30 reduced to give an aminonitrobenzamide disulfide.

WO 95/19970

PCT/US95/00911

-39-

Treatment of this with borohydride, and then formic acid cyclizes the thiazole ring, to give the benzothiazole derivative. Reduction of the second nitro group followed by orthoformate cyclization gives the desired tricyclic pyrimidone. Activation of the 4-oxo group with POCl₃ or other suitable chlorinating agent followed by displacement with the appropriate amine gives the desired compounds.

Scheme 7 - Route for Group 7

10 Nitration of 7-chloroquinazol-4-one at the 6-position by methods familiar to one skilled in the art is followed by displacement of the 7-chloro compound with ammonia. If a 3,N-alkyl substituent is required, an appropriate primary amine can be used instead of ammonia. Reduction with Pearlman's catalyst gives 6,7-diaminoquinazolone which on treatment with formic acid cyclizes to the imidazoloquinazolone. Phosphorus pentasulfide followed by methyl iodide activates the 4-position, and the synthesis is completed by displacement of the 4-methylthio group by an appropriate amine.

Scheme 8 - Route to Preferred Group 10 [4,3-g] Isomers

2,4-Dimethylaniline is diazotized, and cyclized to a benzopyrazole. Nitration of this, followed by chromic acid oxidation and RanNi reduction of the nitro group gives the desired anthranilic acid derivative. This is cyclized to the pyrimidone with formamidine, and activated and displaced at the 4-position in the usual fashion.

WO 95/19970

PCT/US95/00911

-40-

Scheme 9 - Route to Preferred Group 10 [3,4-g] Isomers

2,5-Dimethylacetanilide is nitrated, and the acetate group is saponified off. Diazotization leads to the desired benzopyrazole, which in turn is
5 oxidized to the corresponding benzoic acid derivative. Catalytic reduction of the nitro group with Pd/C is followed by formamidine acetate ring cyclization. The pyrimidone is activated to displacement in one of the usual fashions, and a suitable amine is then
10 introduced at the 4-position to give the desired compound.

Scheme 10 - Route to Preferred Group 11 [4,5-g] Isomers

6,7-Diaminoquinazoline is prepared as described above in Scheme 7. This compound can be
15 cyclized to the triazoloquinazolone via a diazotization, and then the carbonyl is activated via phosphorus pentasulfide and methyl iodide, as described previously and displaced with an appropriate amine to give the desired product.

20 Scheme 11 - Route to Preferred Group 13 A & E Nitrogen

6,7-Diaminoquinazoline is prepared as described above. This compound can be cyclized to a
25 pyrazinoquinazolone by treatment with 2,5-dihydroxy-1,4-dioxane, and then the carbonyl is activated via phosphorus pentasulfide and methyl iodide, as described previously and displaced with an appropriate amine to give the desired product.

WO 95/19970

PCT/US95/00911

-41-

Scheme 12 - Route to Preferred Group 13 B & E Nitrogen

- Reaction of 1,3-diaminobenzene with chloral and hydroxylamine, followed by cyclization with conc. sulfuric acid gives the bis-isatin type tricycle.
- 5 Oxidation with hydrogen peroxide gives the symmetric diaminodiacid. This is doubly cyclized with formamidine, and converted to the corresponding dichloride with POCl₃ or equivalent. Monodisplacement with the desired amine, can be followed by
- 10 displacement of the remaining chloride hydrogenolytically or by a suitable nucleophile to put in R⁵.

Scheme 13 - Route to Preferred Group 33 [4,5-f] Isomer

- Nitration of 6-acetamidoquinazol-4-one gives
- 15 the 5-nitro derivative. Hydrolysis of the amide with dilute HCl, followed by reduction with Pearlman's catalyst gives the 5,6-diaminoquinazolone. Fusion of the imidazole ring by a formic acid gives the parent ring skeleton, and then the carbonyl is activated via
- 20 phosphorus pentasulfide and methyl iodide, as described previously and displaced with an appropriate amine to give the desired product.

Scheme 14 - Route to Preferred Group 33 [4,5-h] Isomer

- Nitration of 7-chloroquinazol-4-one by means
- 25 obvious to one skilled in the art gives the 8-nitro derivative as a minor product. This is purified and the chlorine is displaced by ammonia under high temperature and pressure to give the 5-amino compound which is then reduced by Pearlman's catalyst (Pd
- 30 hydroxide on carbon) to the 7,8-diaminoquinazolone.

WO 95/19970

PCT/US95/00911

-42-

Fusion of the imidazole ring by a formic acid derivative gives the parent ring skeleton, and then the carbonyl is activated via phosphorus pentasulfide and methyl iodide, as described previously and
5 displaced with an appropriate amine to give the desired product.

Scheme 15 - Route to Preferred Group 39 [3,2-d] Isomer

2-Fluorobenzonitrile or a suitably substituted derivative of it is treated with ethyl
10 thioglycollate and a base in a dipolar aprotic solvent to give an ethyl 3-aminobenzothiophene-2-carboxylate derivative. This is cyclized to the desired benzothienopyrimidone with formamide, and the carbonyl
15 is replaced by chlorine using standard techniques, and the chloride is displaced by an appropriate amine to give the desired compounds, or precursors that can readily be converted into them.

Scheme 16 - Route to Preferred Group 39 [3,2-d] Isomer

In a variant of the route described in
20 Scheme 15, lithiation of a suitably substituted fluorobenzene ortho to the fluorine atom is followed by carbonylation. The aldehyde is converted onto a suitable 2-fluorobenzonitrile derivative by oxime formation and dehydration. Alternatively the initial
25 anion can be carboxylated and the resulting acid can be converted via the amide to the desired nitrile. This is then put through the sequence described in Scheme 15, to prepare derivatives which could not be obtained by substitution on 2-fluorobenzonitrile.

WO 95/19970

PCT/US95/00911

-43-

Scheme 17 - Route to Preferred Group 39 [2,3-d] Isomer

Commercially available 4,6-dichloropyrimidine can be monodisplaced with 2-bromobenzenethiolate to give a diarylsulfide. This
5 compound can be metalated at the 5-position of the pyrimidine ring with LDA, and quenched with Me₃SnCl, to form a halostannane. This halostannane is intramolecularly Stille coupled to give the desired 4-chlorobenzothieno[2,3-d]pyrimidine, from which
10 chlorine can be displaced to give the desired product.

Scheme 18 -Route to Preferred Group 41 [3',2':2,3][4,5-d] Isomer

Halogen-metal exchange on 3-bromothiophene in ether at low temperature, followed by treatment
15 with sulfur and then methyl bromoacetate gives methyl (thien-3-ylthio)acetate. Vilsmeier formylation using N-methylformanilide introduces a 2-formyl group on the thienyl ring, without inducing aldol cyclization. Reaction of the aldehyde to the oxime, followed by
20 mesyl chloride/NEt₃, dehydration gives the corresponding nitrile, which cyclizes to methyl 3-aminothieno[3,2-b]thiophene-2-carboxylate on heating to 100°C in DMSO with NEt₃. Pyrimidone fusion is carried out with
25 formamide or an equivalent thereof, and the 4-keto substituent is activated and displaced in the usual manner to give the desired products.

Scheme 19 -Route to Preferred Group 41 [2',3':2,3][5,4-d] Isomer

Metalation of 3-bromothiophene with LDA
30 occurs at the 2-position. Quenching of this anion

WO 95/19970

PCT/US95/00911

-44-

with 1 equivalent of sulfur, followed by one equivalent of 4,6-dichloropyrimidine gives the thienopyrimidosulfide. Selective metalation with LDA at the 5-position of the pyrimidine ring, followed by
5 stannylation gives a precursor for Stille coupling. After the coupling the 4-chlorine is displaced with the appropriate amine to give the desired product.

Scheme 20 -

Route to Preferred Group 44 [4',5': 2,3][4,5-d] Isomer

10 Reaction of thiazolidin-2,4-dione with POCl₃ and DMF gives 2,4-dichlorothiazole-5-carbaldehyde. Protection of the aldehyde as an acetal is followed by selective removal of the 2-chlorine by halogen-metal
15 exchange and hydrolysis. The aldehyde is oxidized up to the corresponding nitrile by oxime formation and dehydration, and 4-chloro-5-cyanothiazole on treatment with fresh 2-mercaptoacetamide in basic conditions gives 6-aminothieno[2,3-d]thiazole-5-carboxamide. This can be cyclized to the tricycle with ethyl
20 orthoformate, and the carbonyl replaced by POCl₃ in the usual manner, and the chloride is then displaced by a suitable amine to give the desired product.

Scheme 21 -

Route to Preferred Group 45 [4',5': 2,3][4,5-d] Isomer

25 1,N-Benzyl-4,5-dibromoimidazole is lithiated with butyl lithium and formylated with DMF. Reaction of the bromoaldehyde with ethyl thioglycollate and base in DMSO leads to the desired aminothienoimidazole. This in turn is annulated again with formamide
30 or an equivalent thereof, and the tricyclic pyrimidone

WO 95/19970

PCT/US95/00911

-45-

is chlorinated at the 4-position and displaced with a suitable amine to give the desired product.

Scheme 22 -**Route to Preferred Group 49 [2',3';2,3] [4,5-d] Isomer**

5 Reaction of 2-chloronicotinonitrile with
methyl thioglycollate gives methyl 3-aminopyrido[2,3-
d]thiophene-2-carboxylate. Fusion of the pyrimidone
ring with formamide gives the corresponding pyrri-
10 do thienopyrimidone, which can then be chlorinated on the
carbonyl and displaced with appropriate amines in the
usual fashion to yield the desired compounds.

Scheme 23 -**Route to Preferred Group 50 [3,2-d] Isomer**

15 A suitably substituted anthranilonitrile
derivative is N-alkylated with ethyl bromoacetate, and
the pyrrole ring is closed by treating the product of
that reaction with KOBu^t, to give ethyl 3-aminoindole-
2-carboxylate. The pyrimidone ring is fused onto this
with formamide, and the carbonyl converted to chloride
20 with POCl₃. Displacement of the chlorine with a
suitable amine gives the desired compound.

Scheme 24 -**Route to Preferred Group 50 [2,3-d] Isomer**

25 The fluoride of 2-fluoronitrobenzene is
displaced by the anion derived from methyl
cyanoacetate and KOBu^t. Mild reduction of the nitro
group to amino is accompanied by spontaneous closure
of the pyrrole ring to give ethyl 2-aminoindole-3-
carboxylate. The pyrimidone ring is fused onto this

WO 95/19970

PCT/US95/00911

-46-

with formamide, and the carbonyl converted to chloride with POCl₃. Displacement of the chlorine with a suitable amine gives the desired compound.

Scheme 25 -**5 Route to Preferred Group 61 [3,2-d] Isomer**

O-Alkylation of 2-cyanophenol with methylbromoacetate, followed by treatment with a strong base gives ethyl 3-aminobenzofuran-2-carboxylate. The pyrimidone ring is fused onto this
10 with formamide, and the carbonyl converted to chloride with Vilsmeier reagent. Displacement of the chlorine with a suitable amine gives the desired compound.

Biology

These compounds are potent and selective
15 inhibitors of the human EGF receptor tyrosine kinase, and other members of the EGF receptor family, including the ERB-B2, ERB-B3 and ERB-B4 receptor kinases, and are useful for the treatment of proliferative diseases in mammals. These inhibitors
20 prevent mitogenesis in cells where mitogenesis is driven by one or more of this family of receptor kinases. This can include normal cells, where it is desired to prevent mitogenesis, as exemplified by the cells transformed by overexpression or mutation of
25 this kinase family as exemplified by poor prognosis breast cancer where overexpression of EGFR, ERB-B2 and ERB-B3 or mutation of ERB-B2 to the oncoprotein NEU is a major factor in cellular transformation. As the preferred compounds are not highly cytotoxic and do
30 not show potent growth inhibitory properties, because of their high specificity toward inhibition of the

WO 95/19970

PCT/US95/00911

-47-

EGFR kinase family, they should have a much cleaner toxicity profile than most anti-cancer and anti-proliferative drugs. Their very different mode of action to current anti-cancer drugs should allow for their use in multiple drug therapies, where synergism with available agents is anticipated.

Compounds of the invention have been shown to be very potent, reversible inhibitors of the EGF receptor tyrosine kinase, by binding with high affinity at the adenosine triphosphate (ATP) binding site of the kinase. These compounds exhibit potent IC_{50} s, varying from 10 micromolar to 50 picomolar, for the tyrosine kinase activity of the enzyme, based on an assay examining phosphorylation of a peptide derived from the phosphorylation site of the protein PLCgamma1, a known EGFR phosphorylation substrate. This data is shown in Table 1.

Biological Data

Materials and Methods

Purification of Epidermal Growth Factor Receptor Tyrosine Kinase - Human EGF receptor tyrosine kinase was isolated from A431 human epidermoid carcinoma cells which overexpress EGF receptor by the following methods. Cells were grown in roller bottles in 50% Delbuco's Modified Eagle and 50% HAM F-12 nutrient media (Gibco) containing 10% fetal calf serum. Approximately 10^9 cells were lysed in two volumes of buffer containing 20 mM 2-(4N-[2-hydroxyethyl]piperazin-1-yl)ethanesulfonic acid (hepes), pH 7.4, 5 mM ethylene glycol bis(2-aminoethyl

WO 95/19970

PCT/US95/00911

-48-

ether) N,N,N',N'-tetraacetic acid, 1% Triton X-100, 10% glycerol, 0.1 mM sodium orthovanadate, 5 mM sodium fluoride, 4 mM pyrophosphate, 4 mM benzamide, 1 mM dithiothreitol, 80 μ g/mL aprotinin, 40 μ g/mL leupeptin and 1 mM phenylmethylsulfonyl fluoride. After centrifugation at 25,000 x g for 10 minutes, the supernatant was equilibrated for 2 h at 4°C with 10 mL of wheat germ agglutinin sepharose that was previously equilibrated with 50 mM Hepes, 10% glycerol, 0.1% Triton X-100 and 150 mM NaCl, pH 7.5, (equilibration buffer). Contaminating proteins were washed from the resin with 1 M NaCl in equilibration buffer, and the enzyme was eluted with 0.5 M N-acetyl-1-D-glucosamine in equilibration buffer, followed by 1 mM urea. The enzyme was eluted with 0.1 mg/ml EGF. The receptor appeared to be homogeneous as assessed by Coomassie blue stained polyacrylamide electrophoretic gels.

Determination of IC₅₀ values - enzyme assays

for IC₅₀ determinations were performed in a total volume of 0.1 mL, containing 25 mM Hepes, pH 7.4, 5 mM MgCl₂, 2 mM MnCl₂, 50 μ M sodium vanadate, 5-10 ng of EGF receptor tyrosine kinase, 200 μ M of a substrate peptide, (Ac-Lys-His-Lys-Lys-Leu-Ala-Glu-Gly-Ser-Ala-Tyr⁴⁷²-Glu-Glu-Val-NH₂, derived from the amino acid (Tyr⁴⁷² has been shown to be one of four tyrosines in PLC (phospholipaseC)-gamma 1 that are phosphorylated by the EGF receptor tyrosine kinase [Wahl, M. I.; Nishibe, S.; Kim, J. W.; Kim, H.; Rhee, S. G.; Carpenter, G., J. Biol. Chem., (1990), 265, 3944-3948.], and peptides derived from the enzyme sequence surrounding this site are excellent substrates for the enzyme.), 10 μ M ATP containing 1 μ Ci of [³²P]ATP and incubated for ten minutes at room temperature. The

WO 95/19970

PCT/US95/00911

-49-

reaction was terminated by the addition of 2 mL of 75 mM phosphoric acid and passed through a 2.5 cm phosphocellulose filter disc to bind the peptide. The filter was washed five times with 75 mM phosphoric acid and placed in a vial along with 5 mL of scintillation fluid (Ready gel Beckman).

Table 1
EGF Receptor Tyrosine Kinase Inhibition

Example #	IC ₅₀ in EGFR
1	<100 pM
2	21 nM
3	760 pM
4	44 nM
5	75 pM
6	6 pM
7	4.1 nM
8	30 pM
9	~10 pM
10	1.7 nM
11	272 nM
12	29 nM
13	191 nM
14	538 nM
15	1.8 nM
16	12.3 nM
17	270 pM
18	36% @ 10 nM

WO 95/19970

PCT/US95/00911

-50-

5

10

15

Example #	IC ₅₀ in EGFR
19	40 nM
20	1.3 μ M
21	732 nM
22	2.11 μ M
23	460 nM
24	419 nM
25	72 nM
26	132 nM
27	264 nM
28	31 nM
29	732 nM
30	4.1 μ M
31	220 nM
32	160 nM
33	4.3 μ M
34	740 nM

Cells

Swiss 3T3 mouse fibroblasts, A431 human epidermoid carcinoma cells, and MCF-7 (Michigan Cancer Foundation human mammary carcinoma cells), SK-BR-3 (human mammary carcinoma cells), MDA-MB-231 and MDA-MB-468 (human mammary carcinoma cells) breast carcinomas were obtained from the American Type Culture Collection, Rockville, Maryland and maintained as monolayers in dMEM (Dulbecco's modified eagle medium)/F12, 50:50 (Gibco/BRL) containing 10% fetal

WO 95/19970

PCT/US95/00911

-51-

bovine serum. To obtain conditioned medium, MDA-MB-231 cells were grown to confluency in an 850 cm² roller bottle and the medium replaced with 50 ml of serum-free medium. After 3 days the conditioned medium was removed, frozen down in aliquots and used as a heregulin source to stimulate erbB-2, 3, 4.

Antibodies

Monoclonal antibodies raised to phosphotyrosine were obtained from Upstate Biotechnology, Inc., Lake Placid, NY. Anti-EGF receptor antibodies were obtained from Oncogene Science, Uniondale, NY.

Immunoprecipitation and Western Blot

Cells were grown to 100% confluency in 100 mm Petrie dishes (Corning). After the cells were treated for 5 minutes with either EGF (epidermal growth factor), PDGF, or bFGF (basic fibroblast growth factor) (20 ng/ml) or 1 ml of conditioned media from MDA-MB-231 cells, the media was removed and the monolayer scraped into 1 ml of ice cold lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 1% triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM sodium pyrophosphate, 30 mM p-nitrophenyl phosphate, 1 mM orthovanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonylfluoride, 10 µg/ml of aprotinin, and 10 µg/ml of leupeptin). The lysate was transferred to a microfuge tube (small centrifuge that holds 1-2 ml plastic centrifuge tubes), allowed to sit on ice 15 minutes and centrifuged 5 minutes at 10,000 x g. The supernatant was transferred to a clean

WO 95/19970

PCT/US95/00911

-52-

microfuge tube and 5 μ g of antibody was added to designated samples. The tubes were rotated for 2 hours at 4° C after which 25 μ l of protein A sepharose was added and then rotation continued for at least 2 more hours. The protein A sepharose was washed 5 times with 50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol and 0.02% sodium azide. The precipitates were resuspended with 30 μ l of Laemmli buffer (Laemmli, NATURE, Vol. 727, pp. 680-685, 1970), heated to 100°C for 5 minutes and centrifuged to obtain the supernatant. Whole cell extracts were made by scraping cells grown in the wells of 6 well plates into 0.2 ml of boiling Laemmli buffer. The extract were transferred to a microfuge tube and heated to 100° C for 5 minutes. The entire supernatant from the immunoprecipitation or 35 μ l of the whole cell extract was loaded onto a polyacrylamide gel (4-20%) and electrophoresis carried out by the method of Laemmli (Laemmli, 1970). Proteins in the gel were electrophoretically transferred to nitrocellulose and the membrane was washed once in 10 mM Tris buffer, pH 7.2, 150 mM NaCl, 0.01% Azide (TNA) and blocked overnight in TNA containing 5% bovine serum albumin and 1% ovalbumin (blocking buffer). The membrane was blotted for 2 hours with the primary antibody (1 μ g/ml in blocking buffer) and then washed 2 times sequentially in TNA, TNA containing 0.05% Tween-20 and 0.05% Nonidet P-40 (commercially available detergent) and TNA. The membranes were then incubated for 2 hours in blocking buffer containing 0.1 μ Ci/ml of [¹²⁵I] protein A and then washed again as above. After the blots were dry they were loaded into a film cassette and exposed to X-AR X-ray film for 1-7 days. Protein A is a bacterial protein that specifically

WO 95/19970

PCT/US95/00911

-53-

bonds certain IgG subtypes and is useful in binding to and isolating antibody-antigen complexes.

Growth Inhibition Assay

Cells (2×10^4) were seeded in 24-well plates (1.7 x 1.6 cm, flat bottom) in two mls of medium with or without various concentrations of drug. Plates were incubated for 3 days at 37° in a humidified atmosphere containing 5% CO₂ in air. Cell growth was determined by cell count with a Coulter Model AM electronic cell counter (Coulter Electronics, Inc., Hialeah, FL).

INHIBITION OF EGF-INDUCED AUTOPHOSPHORYLATION IN A431 EPIDERMOID CARCINOMA CELLS AND CONDITIONED MEDIA-INDUCED AUTOPHOSPHORYLATION IN SK-BR-3 BREAST TUMOR CELLS BY COMPOUNDS OF THE CURRENT INVENTION

Example #	EGFR IC ₅₀ nM	A431 IC ₅₀ nM	SKBR-3 IC ₅₀ nM
1	<0.1	17	ND
6	0.008	46	55
8	0.03	26	10
10	1.7	31	~700
15	1.8	170	ND
17	0.27	86	23
19	40	ND	~1500
25	72	93	1000
28	31	630	10
29	732	109	1100

The gels shown in the drawings, developed as detailed in the experimental section, demonstrate the efficacy of compounds of the current invention at blocking certain EGF-stimulated mitogenic signalling

WO 95/19970

PCT/US95/00911

-54-

events in whole cells. The numbers to the left of gels indicate the positions of molecular weight standards in kiloDaltons. The lane labelled control shows the degree of expression of the growth-related signal in the absence of EGF stimulation, whereas the lane labelled EGF (or PDGF or b-FGF) shows the magnitude of the growth factor-stimulated signal. The other lanes show the effect of the stated quantities of the named drug on the growth factor-stimulated activity being measured, demonstrating that the compounds of the present invention have potent effects in whole cells, consistent with their ability to inhibit the tyrosine kinase activity of the EGF receptor.

See also the results as shown in Figures 1-8.

**ANTIPROLIFERATIVE PROPERTIES OF
TYROSINE KINASE INHIBITORS IC₅₀ (nM)**

	Example 6	Example 17
B104-1-1	3200	2900
SK-BR-3	200	1800
MDA-468	20000	1800

B104-1-1 - NIH-3T3 mouse fibroblasts transfected by the neu oncogene: Stern et al., SCIENCE, 234, pp. 321-324 (1987);

SK-BR-3 - Human breast carcinoma overexpressing erbB-2 and erbB-3;

MDA-468 - Human breast carcinoma overexpressing the EGF receptor.

WO 95/19970

PCT/US95/00911

-55-

Soft Agar Clonogenic Assays

Cell monolayers were exposed to the appropriate compound for 1-3 days and were then washed free of drug with warmed serum-free media. The cells
5 were trypsinised and 10,000/mL were seeded into DMEM/F12 media containing 10% fetal calf serum and 0.4% agarose, but no drug. One ml of this solution was placed over a bottom layer of the same medium containing 0.8% agarose in a 35 mm Petri dish, and was
10 incubated at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. After 3 weeks colonies were counted using an image analyzer for quantification. See Figure 9.

It is to be appreciated that the compounds
15 described herein can be used in combination with other components to enhance their activity. Such additional components are anti-neoplastic materials as, doxorubicin, taxol, cis platin, and the like.

It has been found that the compounds
20 described herein may inhibit both the erb-B2 and erb-B4 receptors and therefore have significantly increased clinical activity advantageously in combination with the aforementioned anti-neoplastic agents.

25 See J. Basalga et al., Antitumor Effects of Doxorubicin in Combination With Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies. *JNCI*, 1993, 85 1327, and Z. Fan et al., Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies

WO 95/19970

PCT/US95/00911

-56-

Plus Cis Diamminedichloroplatinum on Well Established
A431 Cell Xenografts. Cancer Res. 1993, 53, 4637.

Chemical Experimental

5 Listed below are preferred embodiments
wherein all temperatures are in degrees Centigrade and
all parts are parts by weight unless otherwise
indicated.

Example 1

4-(3-bromoanilino)benzo[g]quinazoline hydrochloride

10 3H-Benzo[g]quinazol-4-one. 3-Amino-2-
naphthoic acid (3.74 g, 20 mmol) in stirred formamide
is heated under N₂ to 135°C for 30 min, and to 175°C
for 2 h. The reaction mixture is poured onto
vigorously stirred dilute NaOH solution (0.2 M, 50
15 mL), containing ice, and the solid is collected by
vacuum filtration, rinsed with water (2 x 25 mL), and
dried in a vacuum oven at 60°C to give benzo[g]-3H-
quinazol-4-one (3.49 g, 89%) as a pale khaki solid.
¹H NMR (DMSO) δ 12.08 (1H, brs), 8.84 (1H, s), 8.24
20 (1H, s), 8.21 (1H, d, J = 7 Hz), 8.10 (1H, d, J = 7
Hz), 8.09 (1H, s), 7.62 (2H, apparent d of pentets, J_d
= 1.3 Hz, J_p = 6.7 Hz).

4-Chlorobenzo[g]quinazoline. A suspension
of benzo[g]-3H-quinazol-4-one (3.49 g, 18 mmol) in
25 POCl₃ (40 mL) was refluxed under N₂ for 3 h. The
volatiles were removed under reduced pressure, and the
residue was partitioned between chloroform (200 mL)
and dilute aqueous Na₂HPO₄ solution (1 M, 50 mL). The
organic phase was filtered through a silica gel plug


WO 95/19970

PCT/US95/00911

-57-

(50 g), and the plug was then eluted with 20% EtOAc in CHCl₃ (500 mL). The combined eluents were concentrated under reduced pressure to give 4-chlorobenzo[g]quinazoline (1.20 g, 31%) as an orange-yellow solid. ¹H NMR (DMSO) δ 9.04 (1H, s), 8.91 (1H, s), 8.65 (1H, s), 8.20-8.09 (2H, m), 7.75-7.60 (2H, m).

4-(3-Bromoanilino)benzo[g]quinazoline hydrochloride. 4-Chlorobenzo[g]quinazoline (214 mg, 1.0 mmol), 3-bromoaniline (213 mg, 1.25 mmol) and NEt₃ (202 mg, 2.0 mmol) in stirred methoxyethanol (5 mL) were heated under N₂ at 95°C for 6 h. The volatiles were removed under reduced pressure and the residual solid was triturated with MeOH. The solid was recrystallized at 0°C from an EtOH/ dilute hydrochloric acid mixture (1:4, 0.05 M acid, 50 mL) after celite filtration to give 4-(3-bromoanilino)-benzo[g]quinazoline hydrochloride (71 mg, 18%) as a yellow-green solid. ¹H NMR (DMSO) δ 14.0 (1H brs), 9.65 (1H, s), 9.01 (1H, s), 8.47 (1H, s), 8.29 (1H, d, J = 8.4 Hz), 8.24 (1H, d, J = 8.4 Hz), 8.18 (1H, slbrs), 7.9-7.82 (2H, m), 7.78 (1H, t, J = 7.5 Hz), 7.58 (1H, d, J = 8 Hz), 7.51 (1H, t, J = 8 Hz).



WO 95/19970

PCT/US95/00911

-58-

Example 24-([R]-1-Phenylethylamino)benzo[g]quinazoline hydrochloride

4-Chlorobenzo[g]quinazoline (107 mg, 0.5 mmol), [R]-1-phenylethylamine (72 mg, 0.6 mmol) and
5 NET_3 (202 mg, 2.0 mmol) in stirred methoxyethanol (2 mL) are heated under N_2 at 100°C for 90 min. On cooling the reaction mixture is diluted with CHCl_3 (10 mL), and is shaken with dilute hydrochloric acid (0.2 M, 15 mL). The heavy yellow precipitate is collected by
10 Buchner filtration, rinsed with water (5 mL), and dried in vacuo at 60°C to give 4-([R]-1-phenylethylamino)benzo[g]quinazoline hydrochloride hydrate (122 mg, 64%) as a yellow solid. ^1H NMR (DMSO) δ 14.75 (1H, brs), 10.85 (1H, d, $J = 8.0$ Hz), 9.61 (1H, s), 8.90
15 (1H, s), 8.36 (1H, s), 8.18 (1H, d, $J = 8.2$ Hz), 7.82 (1H, t, $J = 7.6$ Hz), 7.74 (1H, t, $J = 7.4$ Hz), 7.56 (2H, d, $J = 7.5$ KHz), 7.39 (2H, t, $J = 7.6$ Hz), 7.30 (1H, t, $J = 7.4$ Hz), 5.92 (1H, pentet, $J = 7.2$ Hz), 1.76 (3H, d, $J = 7.2$ Hz).

20 Example 34-(3-Bromoanilino)pyrrolo[3,2-g]quinazoline

N-(5-(E,2-dimethylaminoethtenyl)-2,4-dinitrobenzoyl)-N',N'-dimethylformamidine. To a solution of
5-methyl-2,4-dinitrobenzamide (Blatt, A. H. J. Org.
25 Chem 1960, 25, 2030.) (2.25 g, 10 mmol) in DMF (10 mL) is added t-butoxy-bis(dimethylamino)methane (6.2 mL, 30 mL). The reaction mixture is stirred at 55°C for 2 h. The solvent is evaporated under reduced pressure and the residue is suspended in water. The precipi-
30 tate is filtered and washed with water and ethyl ether to give N-(5-(E,2-dimethylaminoethtenyl)-2,4-dinitro-

WO 95/19970

PCT/US95/00911

-59-

benzoyl)-N'N'-dimethylformamidine, 2.76 g (84%). ¹H NMR (DMSO) δ 8.55 (1H, s), 8.47 (1H, s), 8.04 (1H, d, J = 13.0 Hz), 7.76 (1H, s), 5.95 (1H, d, J = 13.0 Hz), 3.21 (3H, s), 3.00 (9H, m).

5 4-Oxo-3H-pyrroloquinazoline. A mixture of
N-(5-(E,2-dimethylaminoethenyl)-2,4-dinitrobenzoyl)-
N'N'-dimethylformamidine (600 mg, 1.79 mmol) and Raney
nickel (200 mg) in THF-MeOH (25 :25 mL) is hydrogenat-
10 ed in a rocking autoclave at 1500 psi at room tempera-
ture for 22 h. The catalyst is filtered off and the
filtrate is concentrated in vacuo. The crude product
is triturated in isopropanol and filtered. The solid
is then washed with isopropanol and ethyl ether and
dried in a vacuum oven at 40 °C to give 4-oxo-3H-
15 pyrroloquinazoline (190 mg, 58%) as a bright red solid
. ¹H NMR (DMSO) δ 11.8 (1H, brs), 11.6 (1H, brs), 8.43
(1H, s), 7.95 (1H, s, J = 3.1 Hz), 7.73 (1H, d, J =
3.4 Hz), 7.55 (1H, s), 6.58 (1H, d, J = 3.4 Hz).

4-(3-Bromoanilino)pyrrolo[3,2-g]quinazoline.
20 4-Oxo-3H-pyrroloquinazoline (100 mg, 0.54 mmol) in
POCl₃ (5 mL) is refluxed under N₂ for 20 h. The re-
sulting dark red solution is cooled to room tempera-
ture and extracted with ethyl acetate (2 x 20 mL).
The organic layer is dried (Na₂SO₄) and concentrated to
25 give a red solid (30 mg). Without further purifi-
cation, this is suspended in 2-propanol (2 mL) con-
taining m-bromoaniline (0.1 mL, 0.8 mmol). The reac-
tion mixture is then refluxed for 1 h. The resulting
bright yellow precipitate is filtered and washed with
30 water and ether to yield 4-(3-bromoanilino)pyrrolo-
[3,2-g]quinazoline (15 mg, 8 %). ¹H NMR (DMSO) δ 11.7
(1H, brs), 10.5 (1H, brs), 8.89 (1H, s), 8.73 (1H,

WO 95/19970

PCT/US95/00911

-60-

brs), 8.16 (1H, s), 7.80 (3H, m), 7.35 (2H, s), 6.77 (1H, s).

Example 4

4-(3-Bromoanilino)thiazolo[5,4-g]quinazoline

5 5,5'-Dithiobis(4-amino-2-nitrobenzamide). A
solution of NaSH in aqueous MeOH (prepared according
to Vogel, in "Elementary Practical Organic Chemistry,
Part 1") is added dropwise with stirring to a solution
10 of 5-chloro-2,4-dinitrobenzamide (5.00 g, 0.020 mmol)
in a mixture of THF/MeOH (1:1, 200 mL) until no
further reaction is observed (TLC analysis). The
solution is then diluted with water and washed with
CH₂Cl₂. The aqueous portion is acidified with
15 concentrated HCl, extracted with EtOAc, and the
extract is worked up to give an oily solid which is
stirred vigorously with MeOH for 3 h. The resultant
precipitate is removed by filtration to give 5,5'-
dithiobis(4-amino-2-nitrobenzamide) (3.11g, 64%) as a
tan powder. ¹H NMR (DMSO) δ 8.88 (1H, brs), 8.33 (1H,
20 brs), 7.99 (1H, s), 7.94 (1H, s), 3.6-3.3 (2H, brs).

5-Nitrobenzothiazole-6-carboxamide. NaBH₄
(0.50 g, 0.013 mmol) is added to a vigorously stirred
suspension of 5,5'-dithiobis(4-amino-2-nitrobenzamide)
(3.00 g, 7.13 mmol) in MeOH (60 mL). After 10 min the
25 solution is acidified with concentrated HCl, extracted
with EtOAc, and worked up rapidly to give 4-amino-5-
mercapto-2-nitrobenzamide as an unstable solid which
is used directly. The crude material is dissolved in
formic acid (50 mL) heated under gentle reflux for 2
30 h, and then concentrated to dryness. The residue is
trituated with MeOH/EtOAc (1:19), and unreacted

WO 95/19970

PCT/US95/00911

-61-

disulfide (1.41 g) is recovered by filtration. The filtrate is concentrated and chromatographed on silica. Elution with EtOAc/petroleum ether (4:1) gives foreruns, while EtOAc gives 5-nitrobenzothiazole-6-carboxamide (1.31g, 41%) as a yellow powder. ¹H NMR (DMSO) δ 9.70 (1H, s), 8.71 (1H, s), 8.52 (1H, s), 8.25 (1H, brs), 7.78 (1H, brs).

Thiazolo[5,4-g]quinazol-4(3H)-one. A solution of 5-nitrobenzothiazole-6-carboxamide (0.30 g, 1.34 mmol) in MeOH/EtOAc (1:1, 25 mL) is hydrogenated over 5% Pd/C at 60 psi for 1 h to give 5-aminobenzothiazole-6-carboxamide. This is immediately dissolved in triethyl orthoformate (30 mL) and the mixture is heated under gentle reflux for 18 h. An equal volume of petroleum ether is added to the cooled solution, precipitating thiazolo[5,4-g]quinazol-4(3H)-one (0.17 g, 57%) as a tan powder. ¹H NMR (DMSO) δ 12.30 (1H, brs), 9.67 (1H, s), 9.00 (1H, s), 8.31 (1H, s), 8.14 (1H, s).

4-(3-Bromoanilino)thiazolo[5,4-g]quinazoline. A suspension of the thiazolo[5,4-g]quinazol-4(3H)-one (0.25 g, 1.23 mmol) in POCl₃ (20 mL) is heated under reflux for 3 h, then concentrated to dryness. The residue is partitioned between saturated aqueous NaHCO₃ and EtOAc, and the organic portion is worked up to give 4-chlorothiazolo[4,5-g]quinazoline (0.21 g, 0.95 mmol) as a yellow solid which is used directly. The crude product and 3-bromoaniline (0.21 mL, 1.90 mmol) are heated under reflux for 45 min in THF/propan-2-ol (1:1, 20 mL) containing a trace of concentrated HCl, and then concentrated to dryness. After trituration with EtOAc,

WO 95/19970

PCT/US95/00911

-62-

the residue is partitioned between saturated aqueous NaHCO₃ and EtOAc and the organic portion is worked up to give 4-(3-bromoanilino)thiazolo[5,4-g]quinazoline (0.19 g, 49%), . ¹H NMR (DMSO) δ 10.05 (1H, brs), 9.74 (1H, s), 9.38 (1H, s), 8.71 (1H, s), 8.48 (1H, s), 8.31 (1H, brs), 7.96 (1H, d, J = 7.7 Hz), 7.39 (1H, t, J = 7.7 Hz), 7.33 (1H, d, J = 7.7 Hz).

Example 5

4-(3-Bromoanilino)oxazolo[5,4-g]quinazoline

10 2,4-Dinitro-5-hydroxybenzamide. A solution of 5-chloro-2,4-dinitrobenzamide (5.50 g, 0.022 mmol) in p-dioxane/methanol (1:1, 120 mL) and 6N aqueous KOH (20 mL) is stirred at room temperature for 2 h. After acidification with concentrated HCl, the mixture is
15 diluted with water and extracted into EtOAc. Workup gives 2,4-dinitro-5-hydroxybenzamide (4.91g, 98%) as yellow cubes. ¹H NMR (DMSO) δ 8.64 (1H, s), 8.16 (1H, brs), 7.81 (1H, brs), 7.13 (1H, s), 5.80 (1H, brs).

4-Oxo-3H-oxazolo[5,4-g]quinazoline. A
20 solution of 2,4-dinitro-5-hydroxybenzamide (4.00 g, 0.018 mmol) in MeOH/EtOAc (1:1, 50 mL) is hydrogenated over 5% Pd/C at 60 psi for 3 h to give 2,4-diamino-5-hydroxybenzamide, which is used directly. Formic acid (50 mL) is added and the solution is heated under
25 reflux for 48 h. then the volatiles are removed under reduced pressure. The residue is triturated with EtOAc to give crude 4-oxo-3H-oxazolo[5,4-g]quinazoline (3.27 g, 97%) as a tan powder which is used directly.

4-Chlorooxazolo[5,4-g]quinazoline. A
30 suspension of 4-oxo-3H-oxazolo[5,4-g]quinazoline (0.98

WO 95/19970

PCT/US95/00911

-63-

g, 5.24 mmol) in POCl₃ (30 mL) is heated under reflux with vigorous stirring for 18 h, and then concentrated to dryness. The residue is partitioned between EtOAc and saturated aqueous NaHCO₃, and the organic portion is
5 worked up to give 4-chlorooxazolo[5,4-g]quinazoline (0.24g, 22%) as a yellow solid which is used directly.

4-(3-Bromoanilino)oxazolo[5,4-g]quinazoline.

A mixture of 4-chlorooxazolo[5,4-g]quinazoline (0.24 g, 1.16 mmol) and 3-bromoaniline (0.25 mL, 2.33 mmol)
10 in a THF/propan-2-ol mixture (1:1, 40 mL) containing a trace of concentrated HCl is heated under reflux for 15 min, then concentration to dryness under reduced pressure. The residue is triturated with EtOAc, and then partitioned between saturated aqueous NaHCO₃, and
15 EtOAc. Workup of the organic portion gives 4-(3-bromoanilino)oxazolo[5,4-g]quinazoline (0.18 g, 33%) as a yellow powder, mp (MeOH) 232 °C (dec.).

Example 6


4-(3-Bromoanilino)imidazolo[4,5-g]quinazoline

20 A mixture of 4-methylthio-6H-imidazo[4,5-g]quinazoline (0.5 g, 1.6 mmol) [Leonard, N.J.; Morrice, A.G.; Sprecker, M.A.; J. Org. Chem., 1975, 40, 356-363], 3-bromoaniline (0.35 g, 2.0 mmol), and 3-bromoaniline hydrochloride (0.4 g, 1.9 mmol) in
25 isopropanol (200 mL) is heated under reflux for 1 h to give a precipitate of 4-(3-bromoanilino)-6H-imidazo[4,5-g]quinazoline hydrochloride (0.63 g, 72 %). ¹H NMR (DMSO) δ 9.93 (1H, brs), 9.01 (1H, s), 8.66 (2H, s), 8.39 (1H, s), 8.04 (2H, m), 7.39 (1H, t, J =
30 7.9 Hz), 7.31 (1H, brd, J = 8.0 Hz).

WO 95/19970

PCT/US95/00911

-64-

Example 74-(3-Bromoanilino)triazolo[4,5-g]quinazoline
hydrochloride

4-Oxo-3H-triazolo[4,5-g]quinazoline. A
5 solution of 6,7-diamino-4-oxo-3H-quinazoline (91 g,
5.7 mmol) [Leonard, N.J.; Morrice, A.G.; Sprecker,
M.A.; J. Org. Chem., 1975, 40, 356-363] in 0.1 M HCl
(250 mL) is cooled to below 10 °C, and a solution of
NaNO₂ (0.41 g, 6 mmol) in water (10 mL) is added over 2
10 min. After 15 min the solution is neutralized with 0.1
M KOH solution to give a precipitate of 4-oxo-3H-
triazolo[4,5-g]quinazoline (1.01 g, 94 %). ¹H NMR
(DMSO) δ 12.22 (2H, m), 8.76 (1H, s), 8.12 (1H, s),
8.07 (1H, s).

15 4-Thiono-3H-triazolo[4,5-g]quinazoline. A
mixture of 4-oxo-3H-triazolo[4,5-g]quinazoline (0.56
g, 3 mmol) and P₂S₅ (1.3 g, 6 mmol) in pyridine (20 mL)
is heated under reflux for 2 h, and the solvent is
removed under reduced pressure. The residue is treated
20 with boiling water (30 mL) to give a yellow solid
which is collected by filtration and dissolved in 0.1
M KOH solution. After filtration to remove insolubles,
the clear yellow solution is neutralized with dilute

WO 95/19970

PCT/US95/00911

-65-

HCl to give 4-thiono-3H-triazolo[4,5-g]quinazoline (0.26 g, 43 %). ¹H NMR (DMSO) δ 9.20 (1H, s), 8.15 (1H, s), 8.14 (1H, s).

4-Methylthiotriazolo[4,5-g]quinazoline. A solution of 4-thiono-3H-triazolo[4,5-g]quinazoline (0.203 g, 1 mmol) and -KOH (0.15 g, 2.7 mmol) in 50 % MeOH-H₂O (15 mL) is treated with MeI (65 μL, 1.0 mmol) and the mixture is stirred at room temperature overnight. The MeOH is removed under vacuum and the solution neutralized with dilute HCl to give crude 4-methylthiotriazolo[4,5-g]quinazoline (0.12 g, 55 %). ¹H NMR (DMSO) δ 8.96 (1H, s), 8.79, (1H, s), 8.40 (1H, s), 2.74 (3H, s).

4-(3-Bromoanilino)-triazolo[4,5-g]quinazoline hydrochloride. A mixture of 4-methylthiotriazolo[4,5-g]quinazoline (0.30 g, 1.38 mmol), 3-bromoaniline (2.1 mmol) and 3-bromoaniline hydrochloride (2.1 mmol) in isopropanol (400 mL) is heated under reflux for 6 h, and the solution is concentrated to give 4-(3-bromoanilino)-triazolo[4,5-g]quinazoline hydrochloride (0.33 g, 63 %). ¹H NMR (DMSO) δ 12.01 (1H, brs), 9.86 (1H, s), 9.02 (1H, s), 8.63 (1H, s), 8.39 (1H, s), 8.13 (1H, dd, J = 1.9, 1.5 Hz), 7.85 (1H, ddd, J = 7.7, 1.9, 1.5 Hz), 7.56 (1H, ddd, J = 8.0, 1.7, 1.5 Hz), 7.41 (1H t, J = 7.8 Hz).

Example 8

4-(3-Bromoanilino)-8,N-methylimidazo[4,5-g]quinazoline

8,N-Methyl-3H-imidazo[4,5-g]quinazolin-4-thione. A mixture of of 8,N-methyl-3H-imidazo[4,5-

WO 95/19970

PCT/US95/00911

-66-

g]quinazolin-4-one (2.32 g, 11.1 mmol) [Lee, C.-H.; Gilchrist, J.H.; Skibo, E.B.; J. Org. Chem., 1986, 51, 4784-4792] and P₂S₅ (3.96 g, 17.8 mmol) in pyridine (25 mL) is heated under reflux for 16 h. The pyridine is removed under vacuum, and the residue is treated with boiling water (50 mL). The precipitate is collected, washed with water, and dissolved in 0.1 M KOH. After filtration to remove insolubles, the clear yellow solution is acidified with AcOH to give 8,N-methyl-3H-imidazo[4,5-g]quinazoline-4-thione (2.12 g, 88 %). ¹H NMR (DMSO) δ 8.91 (1H, s), 8.53 (1H, s), 8.12 (1H, s), 7.91 (1H, s), 3.93 (3H, s).

8,N-Methyl-4-methylthioimidazo[4,5-g]quinazoline. MeI (0.61 ml, 9.5 mmol) is added to a solution of 8,N-methyl-3H-imidazo[4,5-g]quinazoline-4-thione (1.87 g, 8.65 mmol) and KOH (0.58 g, 10 mmol) in 100 ml 50 % MeOH-H₂O, and the resulting mixture is stirred at room temperature for 30 min. The precipitated product is filtered off, and dried, to give 8,N-methyl-4-methylthioimidazo[4,5-g]quinazoline (1.89 g, 82 %). ¹H NMR (DMSO) δ 8.96 (1H, s), 8.64 (1H, s), 8.39 (1H, s), 8.16 (1H, s), 3.98 (3H, s), 2.74 (3H, s).


4-(3-Bromoanilino)-8,N-methylimidazolo[4,5-g]quinazoline. A mixture of 8,N-methyl-4-methylthioimidazo[4,5-g]quinazoline (1.50 g, 6.5 mmol), 3-bromoaniline (1.7 g, 10 mmol), and 3-bromoaniline hydrochloride (2.1 g, 10 mmol) in isopropanol (400 mL) is heated under reflux for 4 h to give a precipitate of the product hydrochloride, which is treated with aqueous NH₃ to give 4-(3-bromoanilino)-8,N-methylimidazo[4,5-g]quinazoline (1.22 g, 52 %). ¹H

WO 95/19970

PCT/US95/00911

-67-

NMR (DMSO) δ 9.86 (1H, s), 9.02 (1H, s), 8.63 (1H, s), 8.54 (1H, s), 8.37 (1H, s), 8.01 (2H, m), 7.36 (1H, t, J = 8.0 Hz), 7.28 (1H, brd), 3.96 (3H, s).



Example 9

5 4-(3-Bromoanilino)-6-N-methylimidazo[4,5-g]quinazoline

2,4-Dinitro-5-methylaminobenzamide. A solution of 5-chloro-2,4-dinitrobenzamide (6.14 g, 25 mmol) [Goldstein, H.; Stamm, R.; *Helv. Chim. Acta*, 10 1952, 35, 1330-1333] and 40% aqueous methylamine (20 mL) in ethanol (80 mL) is heated in a sealed pressure vessel at 100 °C for 2 h. After cooling, dilution with water gives 2,4-dinitro-5-methylaminobenzamide (5.89 g, 98 %). ¹H NMR (DMSO) δ 8.88 (1H, q, J = 4.9 Hz), 15 8.76 (1H, s), 8.07 (1H, brs), 7.77 (1H, brs), 6.98 (1H, s), 3.07 (3H, d, J = 5.0 Hz)

6-N-methyl-3H-imidazo[4,5-g]quinazolin-4-one. A suspension of 2,4-dinitro-5-methylaminobenzamide (4.80 g, 20 mmol) in ethanol and 20 formic acid (2.5 mL, 66 mmol) is hydrogenated over 5% Pd/C, and the solvent is removed under reduced pressure. The resulting crude salt is dissolved in formic acid (100 mL) and the mixture is heated under

WO 95/19970

PCT/US95/00911

-68-

reflux for 2 h. The formic acid is removed under reduced pressure, and the residue is dissolved in the minimum volume of 0.1 M HCl. After clarification with charcoal and filtration through celite, the aqueous solution is neutralized with dilute aqueous NH_3 , and allowed to stand overnight, to give 6,N-methyl-3H-imidazo[4,5-g]quinazolin-4-one (2.99 g, 75 %). ^1H NMR (DMSO) δ 11.91 (12H, brs), 8.50 (1H, s), 8.33 (1H, s), 8.00 (1H, s), 7.89 (1H, s), 3.95 (3H, s).

10 6,N-Methyl-3H-imidazo[4,5-g]quinazolin-4-thione. A mixture of 6,N-methyl-3H-imidazo[4,5-g]quinazolin-4-one (2.50 g, 12.5 mmol) and P_2S_5 (5.55 g, 25 mmol) in pyridine (30 mL) is heated under reflux for 16 h, and the pyridine is removed under reduced pressure. The residue is treated with boiling water (50 mL), and the resulting yellow precipitate is collected by filtration and dissolved in 0.1 M KOH solution. After filtration to remove insolubles, the solution is neutralized with NH_4Cl to give 6,N-methyl-3H-imidazo[4,5-g]quinazolin-4-thione (1.58 g, 59 %). ^1H NMR (DMSO) δ 13.65 (1H, brs), 8.76 (1H, s), 8.61 (1H, s), 8.11 (1H, s), 7.98 (1H, s), 3.99 (3H, s).

25 6,N-Methyl-4-methylthioimidazo[4,5-g]quinazoline. A solution of 6,N-methyl-3H-imidazo[4,5-g]quinazolin-4-thione (1.08 g, 5 mmol) and KOH (0.40 g, 7 mmol) in 50 % aqueous MeOH (100 mL) is treated with MeI (0.33 mL, 5.3 mmol) and the resulting mixture is stirred at room temperature for 1 h. The methanol is then removed under reduced pressure, and the residual aqueous solution is kept at 5 °C overnight to give crystals of 6,N-methyl-4-methylthioimidazo[4,5-g]quinazoline (0.62 g, 54 %). ^1H

WO 95/19970

PCT/US95/00911

-69-

NMR (DMSO) δ 8.93 (1H, s), 8.67 (1H, s), 8.22 (1H, s), 8.21 (1H, s), 4.01 (3H, s), 2.74 (3H, s).

5 4-(3-Bromoanilino)-6,N-methylimidazo[4,5-g]quinazoline hydrochloride. A mixture of 6,N-methyl-4-methylthioimidazo[4,5-g]quinazoline (0.3 g, 1.3 mmol), 3-bromoaniline (0.34 g, 1.95 mmol), and 3-bromoaniline hydrochloride (0.41 g, 1.95 mmol) in isopropanol (400 mL) is heated under reflux for 6 h. After cooling the precipitated solid is collected by
10 filtration and recrystallized from EtOH to give 4-(3-bromoanilino)-6,N-methylimidazo[4,5-g]quinazoline hydrochloride (0.43 g, 85 %). ^1H NMR (DMSO) δ 11.66 (1H, brs), 9.43 (1H, s), 8.96 (1H, s), 8.80 (1H, s), 8.19 (1H, s), 8.16 (1H, brs), 7.89 (1H, brd, $J = 7.1$ Hz),
15 7.54-7.43 (2H, m), 4.05 (3H, s).

Example 10

4-(3-Bromoanilino)pyrazino[2,3-g]quinazoline

7-Acetamido-6-nitro-3H-quinazolin-4-one. A solution of 7-amino-6-nitro-3H-quinazolin-4-one (5.90 g, 28.6 mmol) [Leonard, N.J.; Morrice, A.G.; Sprecker, M.A.; *J. Org. Chem.*, 1975, 40, 356-363] in a mixture
20 of glacial acetic acid (300 mL) and acetic anhydride (100 mL) is heated under reflux for 6 h, and water (100 mL) is added. The solution is then concentrated
25 to a small volume to give 7-acetamido-6-nitro-3H-quinazolin-4-one (5.37 g, 76 %). ^1H NMR (DMSO) δ 10.51 (1H, brs), 8.57 (1H, s), 8.24 (1H, s), 7.97 (1H, s), 2.15 (3H, s).

30 7-Acetamido-4-(3-bromoanilino)-6-nitroquinazoline. A solution of 7-acetamido-6-nitro-

WO 95/19970

PCT/US95/00911

-70-

3H-quinazolin-4-one (5.00 g, 20 mmol) in POCl₃ (250 mL) is heated under reflux for 2 h, the excess of POCl₃ is removed under vacuum, and the residue is dissolved in CH₂Cl₂ and washed with aqueous Na₂CO₃ solution. Workup gives the crude 4-chloro derivative, which is coupled directly with 3-bromoaniline in isopropanol as above, and the resulting hydrochloride is converted directly to the free base, by treatment with aqueous NH₃, to give 7-acetamido-4-(3-bromoanilino)-6-nitroquinazoline (3.60 g, 45 %). ¹H NMR (DMSO) δ 10.56 (1H, s), 10.29 (1H, s), 9.34 (1H, s), 8.70 (1H, s), 8.19 (1H, brs), 7.97 (1H, s), 7.88 (1H, d, J = 6.0 Hz), 7.43-7.35 (2H, m), 2.13 (3H, s).

7-Amino-4-(3-bromoanilino)-6-nitroquinazoline. A solution of 7-acetamido-4-(3-bromoanilino)-6-nitroquinazoline (1.50 g, 3.73 mmol) and KOH (2 g) in MeOH (190 mL) and H₂O (10 mL) is heated under reflux for 30 min, and the solvent volume is reduced to give 7-amino-4-(3-bromoanilino)-6-nitroquinazoline (1.17 g, 87 %). ¹H NMR (DMSO) δ 10.17 (1H, brs), 9.43 (1H, s), 8.43 (1H, s), 8.15 (1H, m brs), 7.86 (1H, d, J = 7.1 Hz), 7.42 (2H, brs), 7.40-7.31 (2H, m), 7.12 (1H, s).

4-(3-Bromoanilino)-6,7-diaminoquinazoline. Iron dust reduction of 7-amino-4-(3-bromoanilino)-6-nitroquinazoline (0.5 g, 1.4 mmol) in 65 % aqueous EtOH containing sufficient aqueous HCl to ensure solubility gives 4-(3-bromoanilino)-6,7-diaminoquinazoline (0.30 g, 65 %). ¹H NMR (DMSO) δ 9.14 (1H, s), 8.27 (1H, s), 8.23 (1H, brs), 7.85 (1H, d, J = 8.0 Hz), 7.31-7.14 (2H, m), 7.29 (1H, s), 6.79 (1H, s), 5.73 (2H, brs), 5.13 (2H, brs).

SUBSTITUTE SHEET (RULE 26)


WO 95/19970

PCT/US95/00911

-71-

4-(3-Bromoanilino)pyrazino[2,3-g]quinazoline. A mixture of 4-(3-bromoanilino)-6,7-diaminoquinazoline (90 mg, 0.27 mmol) and 1,4-dioxane-2,3-diol (0.2 g, 1.6 mmol) [Venuti, M.C.; Synthesis, 1982, 61-63] in MeOH (20 mL) is stirred at room temperature overnight to give a precipitate of 4-(3-bromoanilino)pyrazino[2,3-g]quinazoline (80 mg, 83 %).

¹H NMR (DMSO) δ 10.45 (1H, brs), 9.52 (1H, s), 9.09 (1H, d, J = 1.6 Hz), 9.06 (1H, d, J = 1.6 Hz), 8.71 (1H, s), 8.44 (1H, s), 8.32 (1H, brs), 7.99 (1H, m), 7.45-7.34 (2H, m).



Example 11

4-(3-Bromoanilino)imidazo[4,5-h]quinazoline hydrochloride

6-Methylthioimidazo[4,5-h]quinazoline. A solution of 3H-imidazo[4,5-h]quinazoline-4-thione (0.41 g, 2 mmol) [Morrice, A.G.; Sprecker, M.A.; Leonard, N.J.; J. Org. Chem., 1975, 40, 363-366] and KOH (0.15 g, 27 mmol) in 50 % MeOH-H₂O (50 mL) is treated with MeI (0.13 mL) and the mixture is stirred at room temperature for 3 h to give a precipitate of 4-methylthioimidazo[4,5-h]quinazoline (0.35 g, 80 %).

¹H NMR (DMSO) δ 13.80 (1H, brs), 9.09 (1H, s), 8.49 (1H, s), 7.98 (1H, d, J = 8.8 Hz), 7.85 (1H, d, J = 8.8 Hz), 2.72 (3H, s).

WO 95/19970

PCT/US95/00911

-72-

4-(3-Bromoanilino)imidazo[4,5-h]quinazoline. A mixture of 4-methylthioimidazo[4,5-h]quinazoline (0.216 g, 1 mmol), 3-bromoaniline (0.25 g, 1.5 mmol), and 3-bromoaniline hydrochloride (0.31 g, 1.5 mmol) in *N*-methylpyrrolidone (50 mL) is heated 120 °C for 2 h. The solvent is removed under vacuum and the residue is triturated with EtOH to give a solid which is recrystallized from MeOH to give 4-(3-bromoanilino)imidazo[4,5-h]quinazoline hydrochloride (0.23 g, 61 %). ¹H NMR (DMSO) δ 11.11 (1H, brs), 8.93 (2H, s), 8.66 (1H, d, *J* = 9.0 Hz), 8.11 (1H, brs), 8.07 (1H, d, *J* = 9.0 Hz), 7.83 (1H, brd, *J* = 6.8 Hz), 7.50-7.40 (2H, m).

Example 12

4-(3-Bromoanilino)imidazo[4,5-f]quinazoline

4-Methylthioimidazo[4,5-f]quinazoline. A solution of 3H-imidazo[4,5-f]quinazoline-4-thione (1.01 g, 5 mmol) [Morrice, A.G.; Sprecker, M.A.; Leonard, N.J.; *J. Org. Chem.*, 1975, 40, 363-366] and KOH (0.36 g, 6.5 mmol) in 50 % MeOH-H₂O (50 mL) is treated with MeI (0.34 mL) and the mixture is stirred overnight at room temperature. The MeOH is removed under vacuum to give a precipitate of 4-methylthioimidazo[4,5-f]quinazoline (0.61 g, 57 %). ¹H NMR (DMSO) δ 13.23 (1H, m), 9.05 (1H, s), 8.60 (1H, s), 8.24 (1H, d, *J* = 8.7 Hz), 7.81 (1H, d, *J* = 8.9 Hz), 2.71 (3H, s).

4-(3-bromoanilino)imidazo[4,5-f]quinazoline. A solution of 4-methylthioimidazo[4,5-f]quinazoline (0.43 g, 2 mmol), 3-bromoaniline (0.5 g, 3 mmol), and 3-bromoaniline hydrochloride (0.63 g, 3 mmol) is

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-73-

heated under reflux for 16 h. The precipitate of hydrochloride salt is converted directly to the free base with aqueous NH_3 , and recrystallized from EtOH to give 4-(3-bromoanilino)imidazo[4,5-f]quinazoline (0.52 g, 77%). ^1H NMR (DMSO) δ 11.53 (1H, brs), 8.79 (1H, s), 8.68 (1H, s), 8.53 (1H, dd, $J = 1.8, 1.9$ Hz), 8.15 (1H, d, $J = 8.8$ Hz), 7.81 (1H, brd, $J = 8.6$ Hz), 7.71 (1H, d, $J = 8.9$ Hz, 1 H), 7.41 (1H, t, $J = 8.0$ Hz), 7.32 (1H, brd, $J = 7.8$ Hz).

10 Example 13

4-Benzylaminobenzothieno[3,2-d]pyrimidine

4-Chlorobenzothieno[3,2-d]pyrimidine (111 mg, 0.5 mmol), (see following experimental) and benzylamine (114 mg, 1.0 mmol) (111 mg, 1.1 mmol) in stirred 2-propanol (2 mL) are heated at reflux under N_2 for 26 h. The mixture is allowed to cool, and the precipitate is collected by Buchner filtration, rinsed with 2-propanol and water and dried in an oven to give 4-benzylaminobenzothieno[3,2-d]pyrimidine (100 mg, 68%) as a white powder. ^1H NMR (DMSO) δ 8.60 (1H, s), 8.51 (1H, t, $J = 5.9$ Hz), 8.31 (1H, ddd, $J = 0.7, 1.4, 8.0$ Hz), 8.17 (1H, ddd, $J = 0.7, 1.8, 8.1$ Hz), 7.68 (1H, ddd, $J = 1.2, 7.0, 8.1$ Hz), 7.59 (1H, ddd, $J = 1., 7.0, 8.1$ Hz), 7.36 (2H, d, $J = 7.4$ Hz), 7.33 (2H, t, $J = 7.3$ Hz), 7.24 (1H, t, $J = 7.2$ Hz), 4.79 (2H, d, $J = 6.0$ Hz).

Example 14

4-([R]-1-Phenylethylamino)benzothieno[3,2-d]pyrimidine

30 Ethyl 3-aminobenzothiophene-2-carboxylate.
2-Fluorobenzonitrile (0.61 g, 5 mmol), ethyl

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-74-

thioglycollate (0.60 g, 5 mmol) and NEt₃ (1.52 g, 15 mmol) are stirred in DMSO (5 mL) at 100°C under N₂ for 3 h. The reaction mixture is poured onto ice-water (50 mL), and the solid is collected by suction
5 filtration, rinsed with water, and air dried to give ethyl 3-aminobenzothiophene-2-carboxylate (0.78 g, 70%) as a grey-brown solid. ¹H NMR (DMSO) δ 8.14 (1H, d, J = 7.7 Hz), 7.88 (1H, d, J = 8.1 Hz), 7.50 (1H, dt, J_d = 1.2 Hz, J_t = 7.5 Hz), 7.39 (1H, dt, J_d = 1.2
10 Hz, J_t = 7.6 Hz), 7.17 (2H, brs), 4.26 (2H, q, J = 7.1 Hz), 1.29 (3H, t, J = 7.1 Hz).

Benzothieno[3,2-d]-3H-pyrimid-4-one: Ethyl 3-aminobenzothiophene-2-carboxylate (764 mg, 3.45 mmol) is heated in formamide (2 mL) under N₂ at 140°C
15 for 2 h, and at 180°C for 20 h. The solution is allowed to cool to 25°C, and the slurry is diluted with EtOH (5 mL). The solid is collected by suction filtration, rinsed with EtOH (2x5 mL), and air dried to give benzothieno[3,2-d]-3H-pyrimid-4-one (0.55 g,
20 79%) as a highly crystalline dark brown solid. ¹H NMR (DMSO) δ 12.85 (1H, brs), 8.35 (1H, s), 8.16 (1H, d J = 7.3 Hz), 7.67 (1H, dt, J_d = 1.6 Hz, J_t = 7.5 Hz), 7.59 (1H, dt, J_d = 1.2 Hz, J_t = 7.5 Hz,).

4-Chlorobenzothieno[3,2-d]pyrimidine. DMF
25 (0.27 g, 3.5 mmol) is added dropwise to a solution of oxalyl chloride (0.44 g, 3.5 mmol) in 1,2-dichloroethane (10 mL), stirred under N₂ at 25°C. When the vigorous gas evolution ceases, benzothieno[3,2-d]-3H-pyrimid-4-one (337 mg, 1.53 mmol) is added and the
30 reaction mixture is heated to reflux. After 20 min, the reaction mixture is allowed to cool, and is then quenched with saturated aqueous NaHCO₃ solution (20

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-75-

mL). The phases are separated, and the aqueous phase is extracted with CHCl_3 (3 x 10 mL). The combined organic phases are washed with water (2 x 10 mL), saturated brine (10 mL), and dried (Na_2SO_4). The solvent is removed under reduced pressure to give 4-chlorobenzothieno[3,2-d]pyrimidine (249 mg, 74%) as a light brown solid. ^1H NMR (CDCl_3) δ 9.09 (1H, s), 8.53 (1H, dd, $J = 1.8, 7.6$ Hz), 7.95 (1H, d, $J = 7.8$ Hz), 7.73 (1H, dt, $J_d = 1.4$ Hz, $J_t = 7.7$ Hz), 7.62 (1H, dt, $J_d = 1.2$ Hz, $J_t = 7.5$ Hz).

4-([R]-1-Phenylethylamino)benzothieno[3,2-d]pyrimidine 4-Chlorobenzothieno[3,2-d]pyrimidine (110.1 mg, 0.5 mmol), [R]-1-phenylethylamine (74 mg, 0.6 mmol) and NEt_3 (111 mg, 1.1 mmol) in stirred propanol (2 mL) are heated at reflux under N_2 for 9 h. The mixture is allowed to cool, and is then purified by preparative tlc on silica, eluting once with 2% MeOH in CHCl_3 . The yellow solid is recrystallized from EtOH at 0°C to give 4-([R]-1-phenylethylamino)benzothieno[3,2-d]pyrimidine, (75 mg, 49%) as pale yellow cubic crystals. ^1H NMR (DMSO) δ 8.53 (1H, s), 8.30 (1H, d, $J = 7.2$ Hz), 8.15 (1H, d, $J = 8.2$ Hz), 7.68 (1H, dt, $J_d = 1.2$ Hz, $J_t = 7.5$ Hz), 7.58 (1H, dt, $J_d = 1$ Hz, $J_t = 7.5$ Hz), 7.44 (1H, dd, $J = 1, 8$ Hz), 7.31 (2H, t, $J = 7.7$ Hz), 7.21 (1 H, tt, $J = 1, 7.7$ Hz), 5.58 (1H, q, $J = 7$ Hz), 1.58 (3H, d, $J = 7$ Hz).

Example 15

4-(3-Bromoanilino)benzothieno[3,2-d]pyrimidine

4-Chlorobenzothieno[3,2-d]pyrimidine (110.1 mg, 0.5 mmol), (see preceding example) 3-bromoaniline (107.2 mg, 0.62 mmol) and NEt_3 (102.8 mg, 1.0 mmol) in


WO 95/19970

PCT/US95/00911

-76-

stirred ethoxyethanol (2 mL) are heated at 110°C under N₂ for 18 h. The solvent is removed under reduced pressure, and the dark oily residue is purified by preparative layer chromatography, eluting once with 2% MeOH in CHCl₃. The major band R_f 0.40 is extracted to give a yellowish solid (147 mg) which is recrystallized from EtOH (20 mL) to give 4-(3-bromoanilino)benzothieno[3,2-d]pyrimidine (70 mg, 39%) as pale beige glistening plates. ¹H NMR (CDCl₃) δ

8.88 (1H, s), 8.49 (1H, dd, J = 1.7, 7.1 Hz), 7.96 (1H, t, J = 1.9 Hz), 7.89 (1H, dd, J = 1.6, 7.0 Hz), (1H, d, J = 7.8 Hz), 7.65 (1H, dt, J_d = 1.5 Hz, J_t = 7 Hz), 7.60 (1H, dd, J = 1.5, 7.5 Hz), 7.57 (1H, dt, J_d = 1.5 Hz, J_t = 7 Hz), 7.40 (1H, dt, J_d = 1.7 Hz, J_t = 8 Hz), 7.28 (1H, t, J = 7.8 Hz), 6.90 (1H, brs).



Example 16

4-(3-Bromoanilino)-8-nitrobenzo[b]thieno[3,2-d]pyrimidine

2-Fluoro-5-nitrobenzonitrile. A mixture of 70% nitric acid and concentrated sulfuric acid (1:1, 30 mL) is added dropwise over 30 min to a solution of 2-fluorobenzonitrile (12.11 g, 0.10 mol) in concentrated sulfuric acid (50 mL), stirred under N₂ at 0°C. After a further 3h at 0°C the yellow solution is poured onto ice (400 g), and the solid is collected by

WO 95/19970

PCT/US95/00911

-77-

Buchner filtration, rinsed with water (4 x 50 mL), and dried in vacuo to give 2-fluoro-5-nitrobenzonitrile (15.43 g, 93%) as a pale yellow crystalline solid. ¹H NMR (CDCl₃) δ 8.56 (1H, dd, J = 2.8, 5.5 Hz), 8.51 (1H, ddd, J = 2.8, 4.4, 9.1 Hz), 7.44 (1H, dd, J = 7.8, 9.0 Hz).

Ethyl 3-amino-5-nitrobenzothiophene-2-carboxylate. 2-Fluoro-5-nitrobenzonitrile (1.664 g, 10 mmol), ethyl thioglycollate (1.21 g, 10 mmol) and NEt₃ (3.06 g, 30 mmol) are stirred in DMSO (5 mL) at 100°C under N₂ for h h. The deep orange-red reaction mixture is poured onto ice-water (50 mL), and the solid is collected by suction filtration, rinsed with water, and dried in a vacuum oven at 60°C to give ethyl 3-amino-5-nitrobenzothiophene-2-carboxylate (2.675 g, 100%) as a bright orange solid. ¹H NMR (DMSO) δ 9.23 (1H, d, J = 2.1 Hz), 8.28 (1H, dd, J = 2.3, 8.9 Hz), 8.10 (1H, d, J = 9.0 Hz), 7.45 (2H, brs), 4.29 (2H, q, J = 7.1 Hz), 1.30 (3H, t, J = 7.1 Hz).

8-Nitrobenzo[b]thieno[3,2-d]-3H-pyrimid-4-one. Ethyl 3-amino-5-benzothiophene-2-carboxylate (2.66 g, 10 mmol) is heated in formamide (10 mL) under N₂ at 190°C for 4 h, and precipitates after 2 h. The solution is allowed to cool to 25°C, and the solid is collected by suction filtration, rinsed with EtOH (2x5 mL), and dried in a vacuum oven at 60°C to give 8-nitrobenzo[b]thieno[3,2-d]-3H-pyrimid-4-one (1.91 g, 77%) as a highly crystalline orange-brown solid. ¹H NMR (DMSO) δ 13.00 (1H, brs), 8.85 (1H, s), 8.45 (3H, s).

WO 95/19970

PCT/US95/00911

-78-

4-Chloro-8-nitrobenzo[b]thieno[3,2-d]pyrimidine. DMF (0.75 g, 10.3 mmol) is added dropwise to a solution of oxalyl chloride (1.27 g, 10 mmol) in 1,2-dichloroethane (25 mL), stirred under N₂ at 25°C. When the vigorous gas evolution ceases, 8-nitrobenzo[b]thieno[3,2-d]-3H-pyrimid-4-one (1.236 g, 5 mmol) is added and the reaction mixture is heated to reflux. After 40 min, the hot reaction mixture is celite filtered, and then recrystallized at 0°C to give 4-chloro-8-nitrobenzothieno[3,2-d]pyrimidine (759 mg, 57%) as a light brown solid. ¹H NMR (DMSO) δ 9.24 (1H, s), 8.99 (1H, d, J = 2.0 Hz), 8.57, 8.53 (1H, 1H, ABq of d, J_{AB} = 9.0 Hz, J_d = 2, 0 Hz).

4-(3-Bromoanilino)-8-nitrobenzo[b]thieno[3,2-d]pyrimidine. 4-Chloro-8-nitrobenzo[b]thieno[3,2-d]pyrimidine (266 mg, 1.0 mmol), 3-bromoaniline (187.4 mg, 1.1 mmol) and NEt₃ (200 mg, 2.0 mmol) in stirred 1-propanol (4 mL) are heated at 110°C under N₂ for 48 h, becoming a thick yellow paste. The mixture is cooled to 0°C, and the solid is collected by Buchner filtration, and air dried to give 4-(3-bromoanilino)-8-nitrobenzo[b]thieno[3,2-d]pyrimidine (275 mg, 69%) as a bright yellow solid. ¹H NMR (DMSO) δ 10.12 (1H, brs), 9.03 (1H, s), 8.88 (1H, d, J = 1.8 Hz), 8.54, 8.52 (1H, 1H, ABq of d, J_{AB} = 7.5 Hz, J_d = 0, 1.8 Hz), 8.18 (1H, d, J = 1.7 Hz), 7.83 (1H, dd, J = 1.5, 7.7 Hz), 7.37, 7.34 (1H, 1H, ABq of d, J_{AB} = 7.7 Hz, J_d = 7.7, 1.5 Hz).


WO 95/19970

PCT/US95/00911

-79-

Example 178-Amino-4-(3-bromoanilino)benzo[b]thieno[3,2-d]pyrimidine

4-(3-Bromoanilino)-8-nitrobenzo[b]thieno-
5 [3,2-d]pyrimidine (97 mg, 0.24 mmol) (see previous
experimental) in THF (75 mL) is hydrogenated at 52 psi
for 3 h, in the presence of Raney nickel (5 mg). The
reaction mixture is filtered, and the filtrate is
concentrated to small volume under reduced pressure,
10 and the residue is purified by preparative thin layer
chromatography on silica, eluting with 5% MeOH in
CHCl₃. The band R_f 0.28 is extracted to give 8-amino-
4-(3-bromoanilino)benzo[b]thieno[3,2-d]pyrimidine
(47.2 mg, 53%) as a yellow solid. ¹H NMR (DMSO) δ
15 9.66 (1H, brs), 8.72 (1H, s), 8.18 (1H, t, J = 1.9
Hz), 7.84 (1H, ddd, J = 1.2, 2.0, 8.1 Hz), 7.78 (1H,
d, J = 8.5 Hz), 7.50 (1H, d, J = 2.2 Hz), 7.33 (1H, t,
J = 8.1 Hz), 7.27 (1H, ddd, J = 1.2, 1.8, 8.0 Hz),
7.02 (1H, dd, J = 2.3, 8.5 Hz), 5.47 (2H, brs).

20 Example 184-(3-Bromoanilino)-9-methoxybenzo[b]thieno[3,2-d]pyri-
midine hydrochloride.

2-Fluoro-6-methoxybenzaloxime. NH₂OH·HCl
(334 mg, 4.76 mmol) is added in portions to a solution

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-80-

of NaHCO₃ (395 mg, 4.7 mmol) in water (10mL) at r.t. To this solution was added dropwise a mixture of 2-fluoro-6-methoxybenzaldehyde (made from 3-fluoroanisole as described in Tetrahedron Lett. 1992, 33, 7499) (725 mg, 4.7 mmol) and EtOH (10 mL). The resulting mixture is stirred at r.t for 2hr. The precipitate is collected by filtration and dried in a vacuum oven at ~50C overnight to give 2-fluoro-6-methoxybenzaloxime (720 mg, 89%). ¹H NMR (DMSO) δ 11.44, (1H, s), 8.16 (1H, s), 7.40, (1H, m) 6.85-6.95 (2H, m), 3.84 (3H, s).

2-Fluoro-6-methoxybenzonitrile. A solution of 2-fluoro-6-methoxybenzaloxime (714 mg, 4.2 mmol) in Ac₂O (3.6 mL) is heated at reflux for 4 hr. The reaction is cooled to r.t. and the volatiles are stripped off to give a beige solid, which is dried at 50 °C in a vacuum oven to give 2-fluoro-6-methoxybenzonitrile (635 mg, 84%). ¹H NMR (DMSO) δ 7.8-7.7 (1H, m), 7.14-7.07 (2H, m), 3.95 (3H, s).

Methyl 3-amino-4-methoxybenzothiophene-2-carboxylate. Methyl thioglycollate (0.18 mL, 1.9 mmol) is added dropwise to a suspension of NaH (60% oil suspension, 176 mg, 4.4 mmol) in DMSO (5 mL), stirred under N₂ at 25 °C. When gas evolution ceases, 2-fluoro-6-methoxybenzonitrile (266 mg, 1.76 mmol) in DMSO 5 mL is added in one portion. After 3 h, the reaction mixture is poured onto ice-water, and the beige precipitate is collected by suction filtration, rinsed and air dried to give methyl 3-amino-4-methoxybenzothiophene-2-carboxylate (345 mg, 83%). ¹H NMR (DMSO) δ 7.44-7.37 (2H, m), 7.00, (2H brs), 6.90 (1H, d, J = 7.7Hz), 3.95 (3H, s), 3.76 (3H, s).

WO 95/19970

PCT/US95/00911

-81-

9-Methoxy-4-oxo-3H-benzothieno[3,2-d]pyrimidine. A mixture of methyl 3-amino-4-methoxybenzothiophene-2-carboxylate (202mg, 0.85mmol) and formamide (2mL) is heated at 135C for 1hr and the temperature is raised to 190C. After 8hr the reaction is cooled to r.t. Upon cooling, black solid forms and is collected by filtration. The precipitate is air dried to give 9-methoxy-4-oxo-3H-benzothieno[3,2-d]pyrimidine (45 mg, 22.5%). ¹H NMR (DMSO) δ 12.0 (1H, brs), 8.31 (1H, s), 7.70-7.55 (2H, m), 7.10 (1H, d, J = 7.7 Hz), 3.97 (3H, s).

4-Chloro-9-methoxybenzothieno[3,2-d]pyrimidine. DMF (0.125 mL, 1.7 mmol) is added dropwise to a solution of (COCl)₂ (0.15 mL, 1.68 mmol) in 1,2-dichloroethane (4.5 mL) at r.t. After gas evolution ceases, 9-methoxy-4-oxo-3H-benzothieno[3,2-d]pyrimidine (73.2 mg, 0.32 mmol) is added. The resulting mixture is heated at reflux for 4hr. After the reaction is cooled to r.t., the black tar is filtered off. The filtrate is stripped to dryness and then mixed with water. A yellow solid forms and is collected via filtration. The solid is washed with water and air dried to give 4-chloro-9-methoxybenzothieno[3,2-d]pyrimidine (53 mg, 66%). ¹H NMR (DMSO) δ 9.17 (1H, s), 7.82-7.78 (2H, m), 7.3-7.2 (1H, m), 4.06 (3H, s).

4-(3-bromoanilino)-9-methoxybenzo[b]thieno[3,2-d]pyrimidine hydrochloride. A mixture of 4-chloro-9-methoxybenzothieno[3,2-d]pyrimidine (53 mg, 0.21 mmol), 2-methoxyethanol (3 mL) and m-bromoaniline (0.03 mL, 0.28 mmol) is heated at 80C for 1 h. The reaction is cooled to r.t. and yellow solid

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-82-

precipitates. The solid is collected by filtration and dried in a vacuum oven at -50C overnight to give 4-(3-bromoanilino)-9-methoxybenzo[b]thieno[3,2-d]pyrimidine hydrochloride (60 mg, 68%). ¹H NMR (DMSO) δ 11.14

5 (1H, brs), 8.95 (1H, s), 8.07 (1H, d, J = 1.7Hz), 7.87 (1H, d, J = 8.2 Hz), 7.80 (1H, d, J = 8.2 Hz), 7.76 (1H, d, J = 7.5 Hz), 7.49 (1H, d, J = 8.2 Hz), 7.44 (1H, t, J = 8.0 Hz), 7.25 (1H, d, J = 8.0 Hz), 4.10 (3H, s).

10 Example 19


4-(3-Bromoanilino)thiazolo[4',5'; 4,5]thieno[3,2-d]pyrimidine

A mixture of 5-chlorothiazolo[4',5';4,5]-thieno[3,2-d]pyrimidine (prepared as described by
15 Athmani and Iddon, *Tetrahedron*, 48, 7689, 1992) (66 mg, 0.29 mmol), 3-bromoaniline (0.033 mL, 0.3 mmol) and 2-methoxyethanol (3 mL) is heated at 95C for 2.5 h and then cooled to room temperature. The reaction is added to water, and the precipitate is collected by
20 Buchner filtration and purified by preparative tlc on silica (2% MeOH/CHCl₃). The major band is extracted with 20% MeOH/CHCl₃. After removal of the solvent under reduced pressure 4-(3-bromoanilino)thiazolo[4',5'; 4,5]thieno[3,2-d]pyrimidine (25 mg, 23%) is obtained.
25 ¹H NMR (DMSO) δ 9.98 (1H, s), 9.67 (1H, s), 8.75 (1H, s), 8.17 (1H, s), 7.82 (1H, d, J = 7.8 Hz), 7.38-7.31 (2H, m).

WO 95/19970

PCT/US95/00911

-83-

Example 204-(3-Chloroanilino)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine

Ethyl 3-aminopyrido[3,2-b]thiophene-2-
5 carboxylate. A solution of 2-chloro-3-cyanopyridine (
0.14 g, 1.0 mmol) in DMSO (2 mL) is added dropwise to
a mixture of ethyl thioglycolate (0.12 mL, 1.1 mmol),
NaH (0.06 g, 1.5 mmol) and DMSO (1 mL) stirred under
N₂ at 25°C. After 3 h the reaction is worked up by
10 pouring the reaction mixture onto stirred ice water.
The light yellow precipitate is collected by Buchner
filtration and dried in a vacuum oven to give ethyl 3-
aminopyrido[3,2-b]thiophene-2-carboxylate (197 mg,
89%). ¹H NMR (DMSO) δ 8.68 (1H, dd, J = 4.6, 1.6 Hz),
15 8.54 (1H, dd, J = 8.2, 1.6 Hz), 7.46 (1H, dd, J = 8.2,
4.5 Hz), 7.31 (2H, brs), 4.3 (2H, q, J = 7.1 Hz), 1.29
(3H, t, J = 7.1 Hz).

3H-Pyrido[3',2':4,5]thieno[3,2-d]pyrimid-4-
20 one. A mixture of ethyl 3-aminopyrido[3,2-
b]thiophene-2-carboxylate (0.92 g, 4.14 mmol) and
formamide (10 mL) is heated at 135°C for 1 h and then
at 190°C for 4 h. The reaction mixture is cooled to
25°C producing a precipitate. The solid is collected
by vacuum filtration and is washed with water and

WO 95/19970

PCT/US95/00911

-84-

dried in a vacuum oven at 60°C to give 3H-pyrido[3',2'; 4,5]thieno[3,2-d]pyrimid-4-one (0.61 g, 72.6%) as yellow-brown needles. ¹H NMR (DMSO) δ 13.0 (1H, brs), 8.86 (1H, dd, J = 4.6, 1.6 Hz), 8.63 (1H, dd, J = 8.0, 1.6 Hz), 8.4 (1H, s), 7.68 (1H, dd, J = 8.1, 4.6 Hz).

4-Chloropyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine. To a solution of (COCl)₂ (1.3 mL, 15 mmol) in 1,2-dichloroethane (75 mL) DMF (1.1 mL, 15 mmol) is added dropwise and stirred under N₂ at 25°C. After gas evolution ceases, 3H-pyrido[3',2'; 4,5]thieno[3,2-d]pyrimid-4-one (0.61 g, 3.0 mmol) is added to the mixture and the temperature is raised to 85°C. After 2 h, the reaction mixture is cooled to 25°C and extracted with CHCl₃. The combined extracts are washed with water, saturated brine and dried (MgSO₄). The solvent is removed in vacuo to give 4-chloropyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine (0.64g, 96%) as a yellow solid. ¹H NMR (DMSO) δ 9.3 (1H, brs), 9.0 (1H, d, J = 1.7 Hz), 8.9 (1H, dd, J = 7.3, 0.8 Hz), 7.8 (1H, dd, J = 4.7, 0.8 Hz).

4-(3-Chloroanilino)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine. A mixture of 4-chloropyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine (0.12 g, 0.54 mmol), 3-chloroaniline (0.06 mL, 0.5 mmol) and 2-ethoxyethanol (5 mL) is heated under N₂ with stirring at 135°C for 3 h. Upon cooling a solid precipitates. The solid is collected by filtration, washed with acetone and dried in a vacuum oven at -80°C to give 4-(3-chloroanilino)pyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine (46 mg, 27%). ¹H NMR (DMSO) δ 9.97 (1H, s), 8.88 (1H, dd, J = 4.6, 1.7 Hz), 8.85 (1H, s), 8.72 (1H, dd, J =

WO 95/19970

PCT/US95/00911

-85-

8.0, 1.7 Hz), 8.08 (2H, t, J = 2.0 Hz), 7.79 (1H, ddd, J = 8.3, 2.0, 0.8 Hz), 7.69 (1H, dd, J = 8.0, 4.6 Hz), 7.43 (1H, t, J = 8.0 Hz), 7.19 (1H, ddd, J = 8.0, 2.0, 0.8 Hz).

5 Example 21

4-(3-bromoanilino)pyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine

 A mixture of 4-chloropyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine (72 mg, 0.32 mmol) (see
10 previous experimental), 3-bromoaniline (0.04 mL, 0.37 mmol) and 2-ethoxyethanol (5 mL) is heated under N₂ with stirring at 135°C for 3 h. Upon cooling a solid precipitates. The solid is collected by filtration, washed with acetone and dried in a vacuum oven at -80°C
15 to give 4-(3-bromoanilino)pyrido[3',2'; 4,5]thieno[3,2-d]pyrimidine (45 mg, 39.4%). ¹H NMR (DMSO) δ 9.96 (1H, s), 8.88 (1H, dd, J = 4.6, 1.7 Hz), 8.85 (1H, s), 8.72 (1H, dd, J = 8.0, 1.7 Hz), 8.20 (1H, t, J = 2.0 Hz), 7.84 (1H, ddd, J = 8.0, 2.0, 1.3 Hz), 7.69 (1H, dd, J = 8.0, 4.7 Hz), 7.39-
20 7.31 (2H, m).

Example 22

4-Anilinoindolo[3,2-d]pyrimidine

 A solution of 4-chloroindolo[3,2-d]pyrimidinehydrochloride (240 mg, 1.0 mmol) [Monge,
25 A.; Palop, J. A.; Goni, T.; Martinez-Crespo, F.; Recalde, I.. J. Het. Chem., 1986, 23, 647-9.], and aniline (0.273 mL, 3 mmol) in ethanol (1 mL) is heated at reflux for 3 h, during which time the
30 reaction becomes a thick suspension. After cooling to

WO 95/19970

PCT/US95/00911

-86-

25C and diluting with ethanol (4 ml) the mixture is filtered, and the crude product washed with water (15 mL), and ethanol (15 mL), giving 274 mg tan solid, which is recrystallized from DMF / water affording
5 pure 4-anilinoindolo[3,2-d]pyrimidine hydrochloride (82 mg, 27%). ¹H NMR (DMSO) : δ 12.79 (1H, brs), 11.04 (1H, brs), 8.94 (1H, s), 8.27 (1H, d, J = 8.2 Hz), 7.96 (2H, d, J = 7.5 Hz), 7.85 (1H, d, J = 8.4 Hz), 7.71 (1H, t, J = 7.7 Hz), 7.49 (2H, t, J = 8.0
10 Hz), 7.41 (1H, t, J = 7.6 Hz), 7.24 (1H, t, J = 7.4 Hz).

Example 234-Benzylaminoindolo[3,2-d]pyrimidine

4-Chloroindolo[3,2-d]pyrimidine
15 hydrochloride (240 mg, 1 mmol, and benzylamine (1 mL) are stirred under a dry nitrogen atmosphere at 150 C for 6 hours, and then concentrated under reduced pressure to give an oily soft solid which is dissolved in EtOAc (20 mL), and washed with saturated sodium
20 bicarbonate solution (20 mL), water (3 X 15 mL), and brine (20 mL). The solution is dried (MgSO₄) and the solvent is removed under reduced pressure. Trituration of the residue with dichloromethane, gives 4-benzylaminoindolo[3,2-d]pyrimidine (190 mg, 69%).
25 ¹H NMR (CDCl₃): δ 10.58 (1H, brs), 8.60 (1H, s), 8.08 (1H, d, J=8.0 Hz), 7.47-7.14 (8H, m), 4.82 (2H, d, J=5.6 Hz), 2.41 (1H, brs).

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-87-

Example 244-([R]-1-Phenylethylamino)indolo[3,2-d]pyrimidine
hydrochloride

4-Chloroindolo[3,2-d]pyrimidine
5 hydrochloride 240 mg, 1 mmol) and (R)-(+)-
methylbenzylamine (1 ml) are stirred under a dry
nitrogen atmosphere at 150 for 5 hours, and then
concentrated under reduced pressure to an oil. This
oil is dissolved in EtOAc (20 ml), and stirred for
10 16 h. The precipitate which forms is collected by
filtration, washed with EtOAc, and dried at 90 in
vacuo to give 4-([R]-1-phenylethylamino)indolo[3,2-
d]pyrimidine hydrochloride (37 mg, 11%). ¹H NMR (DMSO):
δ 10 (1H, s), 9.14 (1H, brs), 8.64 (1H, s), 8.16 (1H,
15 d, J = 8.0 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.63-7.59
(1H, m), 7.50 (2H, d, J = 7.2 Hz), 7.38-7.24 (4H, m),
5.59 (1H, p, J = 7.0 Hz); 1.64 (3H, d, J = 7.0 Hz).

Example 254-(3-Bromoanilino)indolo[3,2-d]pyrimidine
20 hydrochloride


4-Chloroindolo[3,2-d]pyrimidine
hydrochloride (240 mg, 1 mmol) and 3-bromoaniline
(0.33 mL, 3 mmol) in ethanol (3 mL) are heated at
reflux under a nitrogen atmosphere for 2h. Filtration
25 and washing of the collected solids with ethanol,
followed by recrystallization from DMF gives 4-(3-
bromoanilino)indolo[3,2-d]pyrimidine hydrochloride
(288 mg, 77%). ¹H NMR (DMSO) δ 12.73 (1H, s), 11.42
(1H, s), 9.02 (1H, s), 8.41 (1H, s), 8.28 (1H, d, J =
30 7.9 Hz), 7.95-7.92 (1H, m), 7.84-7.82 (1H, d, J = 8.6
Hz), 7.74-7.69 (1H, m), 7.40-7.47 (3H, m).

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-88-

Example 264-(3-Bromoanilino)-5,N-methylindolo[3,2-d]pyrimidine hydrochloride

A solution of 4-chloro-5,N-methylindolo[3,2-d]pyrimidine (Kadushkin, A.V.; Nesterova, I.N.; Golovko, T.V.; Nikolaeva, I.S.; Pushkina, T.V.; Fomina, A.N.; Sokolova, A.S.; Chernov, V.A.; Granik, V.G. Khim. -Farm. Zh. 1990, 24, 18-22) (218 mg, 1 mmol) and 3-bromoaniline (0.33 mL, 3 mmol) in 2-propanol (7 mL) containing 0.5% HCl gas is heated at reflux for 3 hr, cooled to 25C, and the solids are filtered and washed with 2-propanol and dried affording 4-(3-bromoanilino)-5,N-methylindolo[3,2-d]pyrimidine hydrochloride (379 mg, 97%), as a bright yellow solid. ¹H NMR (DMSO) δ 9.80 (1H, s), 8.83 (1H, s), 8.34 (1H, d, J = 8.0 Hz), 7.95-7.90 (2H, m), 7.79-7.68 (3H, m), 7.45-7.41 (3H, m), 4.27 (3H, s).

Example 274-Anilinoindolo[2,3-d]pyrimidine

4-Chloroindolo[2,3-d]pyrimidine hydrochloride (R. G. Glushkov et. al., Khim.-Farm. Zh., 1967, 1(9), 25-32) (240 mg, 1 mmol) and aniline (0.27 mL, 3 mmol) in ethanol (1 mL) are heated under

WO 95/19970

PCT/US95/00911


-89-

reflux for 6 h. The solvent is evaporated under reduced pressure, and the residue triturated with EtOAc to afford a tan powder which is filtered, and washed with cold ethanol. Recrystallization from
5 acetone / pet. ether gives 4-anilinoindolo[2,3-d]pyrimidine (49 mg, 19 %). ^1H NMR (DMSO) δ 1H, s), 8.84 (1H, s), 8.43 (1H, s), 8.37 (1H, d, $J = 8.0$ Hz), 7.74 (2H, d, $J = 7.7$ Hz), 7.52-7.08 (6H, m).

Example 28

10 4-(3-Bromoanilino)indolo[2,3-d]pyrimidine
hydrochloride

4-Chloroindolo[2,3-d]pyrimidine hydrochloride (240 mg, 1 mmol) and 3-bromoaniline (0.33 mL, 3 mmol) in ethanol (3 mL) are heated under
15 reflux for 2h. The solids are collected by suction filtration, washed with ethanol and dried to give 4-(3-bromoanilino)indolo[2,3-d]pyrimidine hydrochloride (248 mg, 73%). ^1H NMR (DMSO) δ 1H, s), 9.02 (1H, s), 8.51 (1H, s), 8.42 (1H, d, $J=7.7$ Hz), 8.08 (1H, t, $J = 1.9$ Hz), 7.82 (1H, d, $J = 8.0$ Hz), 7.53 (1H, d, $J=7.9$ Hz), 7.46 (1H, dt, $J_d = 1.0$ Hz, $J_t = 7.6$ Hz),
20 7.36-7.27 (3H, m).



SUBSTITUTE SHEET (RULE 26)


WO 95/19970

PCT/US95/00911

-90-

Example 294-(3-Bromoanilino)-9,N-methylindolo[2,3-d]pyrimidine.

4-Chloro-9,N-methylindolo[2,3-d]pyrimidine (Portnov, Yu. N.; Bulaga, S.N.; Zabrodnyaya, V.G.; Smirnov, L. D. *Khim. Geterotsikl. Soedin.*, 1991, 3, 400-2)
5 (220 mg, 1 mmol) and 3-bromoaniline (0.33 mL, 3 mmol) in 2-propanol, containing 0.5% (w : w) HCl gas, (7 mL) is heated under reflux for 6h. After removal of solvent under reduced pressure, the residue is
10 suspended in CHCl₃ (50 mL), and washed with 1% aqueous NaOH solution (25 mL), and H₂O (2 X 20 mL), dried (MgSO₄), and concentrated under reduced pressure. Column chromatography (SiO₂) with CHCl₃ gives the
product as a light tan foam, which slowly crystallizes
15 upon standing at 25 C. Recrystallization from diisopropyl ether (~30 ml) affords 4-(3-bromoanilino)-9,N-methylindolo[2,3-d]pyrimidine (220 mg, 65%) as a fluffy white solid. ¹H NMR (CDCl₃) δ s,s,m, 3.96 (3H, s).

20 Example 304-(3-Bromoanilino)-9N-(2-N,N-diethylaminoethyl)pyrimido[2,3-d]indole bis hydrochloride

4-Chloro-9N-(2-(N,N-diethylamino)ethyl)-indolo[2,3-d]pyrimidine. A suspension of 4-chloroin-

WO 95/19970

PCT/US95/00911

-91-

dolo[2,3-d]pyrimidine hydrochloride (407 mg, 2 mmol),
2-N,N-diethylaminoethyl chloride hydrochloride (413
mg, 2.4 mmol), anhydrous cesium carbonate (1.95 g, 6
mmol) and 4 molecular sieves (1.5 g) in acetone (6 mL)
5 are heated at reflux under a nitrogen atmosphere for
1.5 h. The mixture is filtered through celite,
washing the filter cake with acetone (4X10 ml),
followed by concentration of the filtrate under
reduced pressure affording a viscous amber oil, which
10 is dissolved in CH₂Cl₂ (20 ml), and washed with water
(2 X 25 mL), dried (MgSO₄), and the solvent is removed
in vacuo. The crude product is chromatographed on
silica, eluting with 4% methanol/chloroform to give 4-
chloro-9N-(2-(N,N-diethylamino)ethyl)indolo[2,3-
15 d]pyrimidine (495 mg, 82%), as a pale yellow oil. ¹H
NMR (DMSO) δ 8.79 (1H, s), 8.41 (1H, d, J = 8.0 Hz),
7.66-7.58 (2H, m), 7.46-7.42 (1H, m), 4.57 (2H, t, J =
6.8 Hz), 2.90 (2H, t, J = 7.1 Hz), 2.63 (4H, d, J =
7.0 Hz), 0.99 (6H, t, J = 7.0 Hz).

20 4-(3-Bromoanilino)-9N-(2-N,N-diethylamino-
ethyl)pyrimido[2,3-d]indole bis hydrochloride. A
suspension of 4-chloro-9N-(2-(N,N-diethylamino)ethyl)-
indolo[2,3-d]pyrimidine (240 mg, 1 mmol) and 3-bromo-
aniline (0.33 mL, 3 mmol) in 2-propanol (7 mL), which
25 contains 0.5% HCl gas, is heated under reflux for 6
hr, and then concentrated to a viscous brown oil which
is dissolved in chloroform (75 mL) and washed with 1 %
aqueous NaOH solution (50 mL), water (50 mL), and
dried (MgSO₄). The solvent is removed under reduced
30 pressure, and the residue is chromatographed on SiO₂,
eluting with 2 % MeOH in CHCl₃ to obtain the free
base of the product as a pale yellow oil (411 mg,
93%). The free base is dissolved in warm ethanol (5

WO 95/19970

PCT/US95/00911

-92-

mL), and is treated with ethanol (2 mL) which had been saturated with HCl gas, affording 4-(3-bromoanilino)-9N-(2-N,N-diethylaminoethyl)indolo[2,3-d]pyrimidine bis hydrochloride. ¹H NMR (DMSO) δ 10.64 (1H, brs), 9.17 (1H, s), 8.60 (1H, s), 8.52 (1H, d, J = 8.0 Hz), 8.07 (1H, s), 7.93 (1H, d), 7.80 (1H, d, J = 7.7 Hz), 7.58 (1H, t, J = 7.7 Hz), 7.41 (1H, t, J = 7.2 Hz), 7.37-7.39 (2H, m), 4.90 (2H, t, J = 7.0 Hz), 3.51 (2H, dd, J = 12.8, 6.5 Hz) 3.31-3.28 (4H, m), 1.25 (6H, t, J = 7.2 Hz).

Example 31

4-(3-Bromoanilino)6-methoxyindolo[2,3-d]pyrimidine

Cyano-(5-methoxy-2-nitrophenyl)acetic acid ethyl ester. To an ice-cold solution of ethyl cyanoacetate (10.9 mL, 102.4 mmol) in anhydrous THF (170 mL) under N₂ is added of potassium tert-butoxide (12.07 g, 107.5 mmol). The formed white suspension is stirred for 15 min then treated with 3-fluoro-4-nitroanisole [Halfpenny, P. R.; Horwell, D. C.; Hughes, J.; Hunter, J. C.; Rees, D. C. J. Med. Chem. (1990), 33, 286-91] (8.86 g, 51.2 mmol). The suspension is heated at reflux for 1.5 h. The solution is poured into H₂O, and the aqueous mixture is acidified to pH 2 with concentrated HCl. The mixture is extracted three times with ether then the combined organic phases are dried (MgSO₄) and concentrated to an oil that is pumped at 0.3 mm for 2 days. The oil is dissolved in dichloromethane and purified by flash silica gel chromatography eluting with dichloromethane. The product fractions are combined and concentrated to leave cyano-(5-methoxy-2-nitrophenyl)acetic acid ethyl ester (14.5 g) as a

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-93-

light yellow oil that is about 93-95% pure. ^1H NMR (CDCl_3): δ 8.29 (1H, d, $J = 9.2$ Hz), 7.22 (1H, d, $J = 2.7$ Hz), 7.04 (1H, dd, $J = 9.2, 2.7$ Hz), 5.69 (1H, s), 4.31 (2H, q, $J = 7.0$ Hz), 1.34 (3H, t, $J = 7.2$ Hz).

5 2-Amino-5-methoxy-1H-indole-3-carboxylic
acid ethyl ester. A solution of cyano-(5-methoxy-2-nitrophenyl)acetic acid ethyl ester (13.2 g, 46.3 mmol, 93-95% pure) in glacial acetic acid (185 mL) is treated with a single charge of zinc dust (12.1 g, 185 mmol). The mixture is heated at 55 °C for 45 min, then treated with more zinc (4 g). After heating for another 105 min, the brown mixture is filtered through a pad of flash silica gel. The pad is washed well with acetic acid and the filtrate is concentrated to a residue that is distributed between dichloromethane and H_2O . The organic phase is washed with 5% aqueous sodium bicarbonate and concentrated to a residue that shows about a 1:1 mixture of products by silica gel thin layer chromatography (dichloromethane:EtOAc, 3:1). The residue is purified by flash silica gel chromatography eluting sequentially with 100:0, 95:5, and 90:10 dichloromethane:EtOAc. The fractions containing the pure higher R_f product are combined and concentrated to a solid that is sonicated in tert-butyl methyl ether. The solids are collected by filtration to give pure 2-amino-5-methoxy-1H-indole-3-carboxylic acid ethyl ester (2.07 g) as an off-white solid. Further chromatography of the combined mother liquor and impure fractions affords 120 mg of additional product. Total yield = 2.19 g (20%). ^1H NMR (DMSO): δ 10.44 (1H, br s, exchanges with D_2O), 7.11 (1H, d, $J = 2.2$ Hz), 6.98 (1H, d, $J = 8.4$ Hz), 6.61 (2H, br s, exchanges with D_2O), 6.48 (1H, dd, $J =$

WO 95/19970

PCT/US95/00911

-94-

8.4, 2.7 Hz), 4.20 (2H, q, $J = 7.0$ Hz), 3.71 (3H, s), 1.32 (3H, t, $J = 7.2$ Hz).

6-Methoxy-3H-indolo[2,3-d]pyrimidine-4-one.

A solution of 2-amino-5-methoxy-1H-indole-3-carboxylic acid ethyl ester (2.15 g (9.2 mmol), sodium methoxide (0.5 g (9.3 mmol), and formamide (200 mL), is heated under N_2 at 220°C for 1.5 h. The solution is cooled to room temperature, stored for 2.5 days, and filtered. The solvent is evaporated by Kugelrohr distillation at 95 °C/0.8 mm. The residual solids are washed with H_2O , then heated in 35 mL of boiling N,N-dimethylformamide. The hot suspension is filtered hot over a pad of flash silica gel. The cooled filtrate is concentrated in vacuo to a solid that is sonicated in about 30 mL of MeOH. The solids are filtered, washed with MeOH, and dried to leave 6-methoxy-3H-indolo[2,3-d]pyrimidine-4-one (1.71 g, 72%) that is about 83 % pure. 1H NMR (DMSO) : δ 12.16 (1H, br s, exchanges with D_2O), 12.04 (1H, br s, exchanges with D_2O), 8.08 (1H, d, $J = 3.4$ Hz, exchanges to s with D_2O), 7.46 (1H, d, $J = 1.9$ Hz), 7.37 (1H, d, $J = 8.7$ Hz), 6.95 (1H, dd, $J = 8.8, 2.5$ Hz), 3.81 (3 H, s).

4-Chloro-6-methoxyindolo[2,3-d]pyrimidine. A suspension of 6-methoxy-3H-indolo[2,3-d]pyrimidine-4-one (800 mg, 3.08 mmol, ~83% pure) and $POCl_3$ (7 mL) is heated at 90 °C for 6 h. The suspension is concentrated to a solid that is evacuated at 1 mm for 1 h. The solids are cooled in a -78 °C bath then treated dropwise with cold H_2O . The bath is removed and the frozen solids are allowed to gradually melt. The solids are filtered, washed well with cold H_2O , and dried to leave 4-chloro-6-methoxyindolo[2,3-d]pyrimi-

WO 95/19970

PCT/US95/00911

-95-

dine (733 mg, 81%) that is about 80% pure. ¹H NMR (DMSO) : δ 12.64 (1H, br s, exchanges with D₂O), 8.74 (1H, s), 7.74 (1H, d, J = 2.4 Hz), 7.57 (1H, d, J = 8.9 Hz), 7.28 (1H, dd, J = 8.9, 2.4 Hz), 3.88 (3H, s).

5

4-(3-Bromoanilino)-6-methoxyindolo[2,3-d]-pyrimidine. A mixture of 4-chloro-6-methoxyindolo[2,3-d]pyrimidine (107 mg, 0.37 mmol, 80% pure), 3-bromoaniline (0.15 mL, 1.4 mmol), N,N-dimethylacetamide (1 mL), and 1 drop of a solution of 2-propanol that is 8.5 molar in HCl is heated under N₂ at 120 °C for 5 h. The solution is concentrated in vacuo to an oily solid that is triturated in 5% aqueous sodium bicarbonate. The solids are collected by filtration, then washed successively with H₂O and EtOAc. The solids are warmed in a small volume of N,N-dimethylformamide and filtered. The filtrate is purified by thick layer silica gel chromatography eluting with 3:2 dichloromethane:EtOAc. The product band is collected and sonicated in EtOAc. The mixture is filtered and the filtrate is concentrated to a solid that is sonicated in MeOH. The solids are collected, washed with MeOH, and dried to give pure 4-(3-bromoanilino)-6-methoxyindolo[2,3-d]pyrimidine (39 mg, 28%) hydrated with 0.7 equivalent of H₂O. ¹H NMR (DMSO) : δ 11.99 (1H, br s, exchanges with D₂O), 8.97 (1H, br s, exchanges with D₂O), 8.44 (1H, s), 8.02 (1H, s), 7.91 (1H, d, J=2.4 Hz), 7.76 (1H, d, J= 8.0 Hz), 7.42 (1H, d, J=8.7 Hz), 7.36 - 7.24 (2H, m), 7.08 (1H, dd, J = 8.7, 2.2 Hz), 3.87 (3H, s).

10

15

20

25

30

WO 95/19970

PCT/US95/00911

-96-

Example 322-Amino-4-(3-bromoanilino)pyrimido[2,3-d]indole

2-Guanidinoindole-3-carboxylic acid ethyl ester hydrochloride. A suspension of 2-aminoindole-3-carboxylic acid ethyl ester (2.04 g, 10.0 mmol), cyanamide (534 mg, 12.7 mmol), and concentrated hydrochloric acid (1 mL) in dioxane (91 mL), are heated under reflux for 48 hr. After the reaction mixture has cooled to 25 °C it is filtered and the solids washed well with dry diethyl ether, and then air dried to give 2-guanidinoindole-3-carboxylic acid ethyl ester hydrochloride (1.08g, 38 %) 2-guanidinoindole-3-carboxylic acid ethyl ester hydrochloride as an off-white solid, mp >250 °C.

2-Amino-4-oxo-3H-indolo[2,3-d]pyrimidine. A mixture of 2-guanidinoindole-3-carboxylic acid ethyl ester hydrochloride (1.00 g, 3.5 mmol) and sodium hydroxide (1.5 g) in water (50 mL) is heated to gentle reflux for 6 hr followed by the addition of sufficient 5 % HCl to adjust the solution to pH 1, and filtration of the resulting mixture through celite, washing the pad with water. The filtrate is extracted with ethyl acetate (3 X 25 mL), and then basified with solid sodium carbonate. The tan precipitate which slowly forms is collected by filtration, washed with water, and dried in vacuo affording 2-amino-4-oxo-3H-indolo[2,3-d]pyrimidine (561 mg, 78%) as light tan crystals, mp > 275 °C.

2-Amino-4-chloroindolo[2,3-d]pyrimidine hydrochloride. A suspension of 2-amino-4-oxo-3H-indolo[2,3-d]pyrimidine (490 mg, 2.5 mmol) and phosphoryl chloride (7 mL, 75 mmol) in dioxane (13 mL) is heated under reflux for 4 hr, then concentrated in

WO 95/19970

PCT/US95/00911

-97-

vacuo. The residue is triturated with ethanol, filtered, and the solids washed with 10 : 1 Ethanol : Ethyl Acetate to give 170 mg (27 %) 2-amino-4-chloroindolo[2,3-d]pyrimidine hydrochloride as a grey solid, mp >250 C.

2-Amino-4-(3-bromoanilino)indolo[2,3-d]pyrimidine. A mixture of 2-amino-4-chloroindolo[2,3-d]pyrimidine hydrochloride (123 mg, 0.6 mmol) and 3-bromoaniline (0.3 mL, 2.8 mmol) in 2-propanol (6 mL) is heated at reflux for 4 hr, filtered through a celite pad, and concentrated in vacuo. The residue is partitioned between ethyl acetate (25 mL) and water (25 mL). The aqueous phase is extracted with further ethyl acetate (2 x 20 mL), followed by washing the combined extracts with 1% aqueous sodium hydroxide (25 mL), water (2 x 40 mL), saturated brine (40 mL), and drying (Na₂SO₄). The solution is evaporated to dryness under reduced pressure to afford 105 mg crude product as a tan powder. The solid is dissolved in a minimum amount of methanol, filtered, and further purified by preparative plate chromatography (SiO₂; 1 : 1, EtOAc : CH₂Cl₂; R_f = .40). After extraction of the product from the silica gel with ethyl acetate, the volume of the warm solution is reduced to minimum, and it is filtered through celite, and the solvent is removed under reduced pressure. The oily solid thus obtained is dissolved in a minimum amount of 2-propanol and allowed to crystallize at 3 C over an 18 h period. The crystals are collected by suction filtration, washed with a small amount of cold 2-propanol, and dried in vacuo to give 2-amino-4-(3-bromoanilino)indolo[2,3-d]pyrimidine (34 mg, 17%). ¹HNMR, (DMSO): δbrs), 8.57 (1H, s), 8.11 (1H, d, J

WO 95/19970

PCT/US95/00911

-98-

= 8.0 Hz), 8.01 (1H, s), 7.94 (1H, d, J = 8.2 Hz), 7.34-7.12 (5H, m), 6.41 (2H, brs).

Example 33

4-(3-Bromoanilino)-9N-(2-N,N-diethylaminoethyl)-6-methoxyindolo[2,3-d]pyrimidine bishydrochloride

4-Chloro-6-methoxy-9H-(2-N,N-diethylaminoethyl)indolo[2,3-d]pyrimidine. A suspension of 4-chloro-6-methoxyindolo[2,3-d]pyrimidine (773 mg, 2.5 mmol, ~80% pure), 2-diethylaminoethyl chloride hydrochloride (582 mg, 3.4 mmol), anhydrous cesium carbonate (2.3 g, 7.1 mmol), 4 molecular sieves (2.1 g), and acetone:N,N-dimethylformamide (12 mL, 2:1) is heated at reflux under N₂ for 16.5 h. The mixture is filtered over Celite® and the filter pad is washed well with acetone. The filtrate is concentrated in vacuo to a viscous oil that is distributed between dichloromethane and H₂O. The organic phase is dried (MgSO₄) and concentrated to an oil that is purified by flash silica gel chromatography eluting first with dichloromethane, then with dichloromethane:MeOH (98:2). The product fractions are combined and concentrated in vacuo to leave 4-chloro-6-methoxy-9H-(2-N,N-diethylaminoethyl)indolo[2,3-d]pyrimidine (667 mg, 80%) as a yellow oil. ¹H NMR (CDCl₃): δ 8.75 (1H, s), 7.87 (1H, d, J=2.4 Hz), 7.47 (1H, d, J = 8.9 Hz), 7.25 (1H, dd, J = 8.9, 2.4 Hz), 4.50 (2H, t, J=7.2 Hz), 3.96 (3H, s), 2.86 (2H, t, J=7.1 Hz), 2.59 (4H, q, J=7.1 Hz), 0.96 (6H, t, J=7.1 Hz).

4-(3-Bromoanilino)-6-methoxy-9H-(2-N,N-diethylaminoethyl)indolo[2,3-d]pyrimidine bishydrochloride. A solution of 4-chloro-6-methoxy-9H-(2-N,N-

WO 95/19970

PCT/US95/00911

-99-

diethylaminoethyl)indolo[2,3-d]pyrimidine (660 mg, 1.98 mmol), 3-bromoaniline (0.52 mL, 4.8 mmol, 0.25 mL of a solution of 2-propanol that is 8.5 molar in HCl, and N,N-dimethylacetamide (4 mL) is heated at 120 °C under N₂ for 2 h. The solution is concentrated in vacuo and the residue is distributed between dichloromethane and 1% aqueous sodium hydroxide. The dichloromethane phase is washed with H₂O, dried (MgSO₄), and concentrated to an oil that is purified by flash silica gel chromatography eluting first with EtOAc, then EtOAc:MeOH:triethylamine (95:5:1). The product fractions are combined and concentrated to leave an oil that is stored at room temperature overnight. The semisolid is treated with an excess of a solution of 2-propanol that is 8.5 molar in HCl. After storage for several hours at room temperature, the solids are collected by filtration, washed with 2-propanol, and dried to leave 4-(3-bromoanilino)-6-methoxy-9H-(2-N,N-diethylaminoethyl)indolo[2,3-d]pyrimidine (727 mg, 65%) as a salt with 2.1 equivalents of HCl and solvated with 0.9 equivalent of H₂O. ¹H NMR (DMSO) : δ 10.55 (1H, br s, exchanges with D₂O), 9.28 (1H, br s, exchanges with D₂O), 8.55 (1H, s), 8.02 (1H, d, J=2.2 Hz), 7.99 (1H, s), 7.84 (1H, d, J= 8.7 Hz), 7.74 (1H, d, J=7.2 Hz), 7.39 - 7.32 (2H, m), 7.21 (1H, dd, J = 8.9, 2.2 Hz), 5.30 (3H, br s, exchanges with D₂O), 4.85 (2H, t, J = 7.2 Hz), 3.90 (3H, s), 3.48 (2H, dd, J = 12.2, 6.4 Hz); 3.35-3.21 (4H, m); 1.23 (6H, t, J = 7.2 Hz).

Example 34

30 4-(3-Bromoanilino)benzofurano[3,2-d]pyrimidine

Methyl 2-(2-cyanophenoxy)ethanoate. Methyl bromoacetate (1.95 mL, 20 mmol) is added dropwise to a

WO 95/19970

PCT/US95/00911

-100-

5 solution of 2-cyanophenol (2.38 g, 20 mmol), and K_2CO_3 (2.78 g, 20.1 mmol) in acetone (100 mL) stirred under N_2 at 25°C. After 24 h, the solid is filtered off and the filtrate is concentrated in vacuo and the residue is dried in a vacuum oven to give methyl 2-(2-cyanophenoxy)ethanoate (3.82 g, 100%) as a beige solid. 1H NMR (DMSO) δ 7.76 (1H, dd, $J = 7.6, 1.7$ Hz), 7.64 (1H, dt, $J_d = 1.6$ Hz, $J_t = 8.0$ Hz), 7.20~7.10 (2H, m), 5.04 (2H, brs), 3.70 (3H, s).

10 Methyl 3-aminobenzo[b]furan-2-carboxylate. A solution of methyl 2-(2-cyanophenoxy)ethanoate (3.82 g, 20 mmol) in DMSO (40 mL) is added dropwise to a suspension of NaH (0.84 g, 21 mmol) and DMSO (10 mL) stirred under N_2 at 25°C. After 10 min the mixture is
15 poured onto ice water and extracted with ether. The combined extracts are washed with water, saturated brine and dried ($MgSO_4$). After removal of the solvent under reduced pressure, methyl 3-aminobenzo[b]furan-2-carboxylate (2.15 g, 56%) is obtained as a yellow solid.
20 1H NMR (DMSO) δ 7.95 (1H, d, $J = 7.7$ Hz), 7.48 (2H, d, $J = 3.4$ Hz), 7.29-7.22 (1H, m), 6.40 (2H, brs), 3.80 (3H, s).

3H-Benzofurano[3,2-d]pyrimid-4-one. A solution of methyl 3-aminobenzo[b]furan-2-carboxylate (0.28 g, 1.36 mmol) in formamide (5 mL) is heated at
25 135°C for 4 h, then the temperature is raised to 170°C. After 4 h the reaction is cooled to 25°C and a dark purple solid precipitates. The solid is collected by vacuum filtration and air dried to give 3H-benzofurano[3,2-d]pyrimid-4-one (118 mg, 46.6%). 1H NMR
30 (DMSO) δ 13.0 (1H, brs), 8.25 (1H, s), 8.05 (1H, d, J

WO 95/19970

PCT/US95/00911

-101-

= 8.1 Hz), 7.84 (1H, d, J = 8.3 Hz), 7.68 (1H, t, J = 7.7 Hz), 7.51 (1H, t, J = 7.7 Hz).

4-Chlorobenzofurano[3,2-d]pyrimidine. DMF (0.23 mL, 3.1 mmol) is added dropwise to a solution of (COCl)₂ (0.28 mL, 3.1 mmol) in 1,2-dichloroethane (15 mL) at 25°C. After gas evolution ceases, 3H-benzofurano[3,2-d]pyrimid-4-one (113 mg, 0.61 mmol) is added. The resulting mixture is heated at reflux for 1 h. After the reaction has cooled to 25°C, water is added and the resulting mixture is extracted with CHCl₃. The combined extracts are washed with water, saturated brine and dried (MgSO₄). The solvent is removed under reduced pressure to give 4-chlorobenzofurano[3,2-d]pyrimidine (116mg, 93%) as a yellow solid. ¹H NMR (DMSO) δ 9.08 (1H, s), 8.30 (1H, d, J = 8.1 Hz), 8.02 (1H, d, J = 8.5 Hz), 7.90, (1H, dt, J_d = 1.3 Hz, J_t = 7.1 Hz), 7.64 (1H, dt, J_d = 1.0 Hz, J_t = 7.8 Hz).

4-(3-Bromoanilino)benzofurano[3,2-d]pyrimidine. A mixture of 4-chlorobenzofurano[3,2-d]pyrimidine (116mg, 0.57 mmol) and 3-bromoaniline (0.07 mL, 0.6 mmol) is heated at 135°C under N₂ in stirred 2-ethoxyethanol for 3 h. The mixture precipitates upon cooling, and the solid is collected and recrystallized from EtOH to give 4-(3-bromoanilino)benzofurano[3,2-d]pyrimidine (15.7 mg, 8%). ¹H NMR (DMSO) δ 10.35 (1H, s), 8.73 (1H, s), 8.34 (1H, t, J = 1.9 Hz), 8.17 (1H, ddd, J = 7.2, 1.2, 0.7 Hz), 7.93 (1H, ddd, J = 8.2, 2.2, 1.0 Hz), 7.88 (1H, d, J = 8.4 Hz), 7.77 (1H, dt, J_d = 1.4 Hz, J_t = 7.2 Hz), 7.56 (1H, dt, J_d = 0.8 Hz, J_t = 8.0 Hz), 7.34 (1H, t, J = 8.0 Hz), 7.27 (1H, ddd, J = 8.0, 2.0, 1.0 Hz).

WO 95/19970

PCT/US95/00911

-102-

The pharmaceutical compositions of the invention can take any of a wide variety of oral and parenteral dosage forms. The dosage forms comprise as the active components an inhibitor as defined previously.

For preparing pharmaceutical compositions, one uses inert, pharmaceutically acceptable carriers that can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances which may also act as dilutents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compounds. In the tablet, the active compounds are mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5% or 10% to about 70% of active ingredients. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compounds with encapsulating materials as carrier, providing a capsule in which the active components (with or without other carriers) are surrounded by carrier, which are thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and

WO 95/19970

PCT/US95/00911

-103-

capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active components in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.

Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation may be subdivided into unit doses containing appropriate quantities of inhibitor and other anti-cancer materials individually or as a combination, i.e., in a mixture. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these in packaged form. Additionally, the unit dosage form may be a dividable form having an inhibitor in one part and other anti-cancer materials in the other part, such as, a dividable capsule, a dividable package, or a two-part ampoule, vial or the like.

WO 95/19970

PCT/US95/00911

-104-

The quantity of an inhibitor in unit dosages of preparation may be varied or adjusted from about 0.01 mg/kg to 100.0 mg/kg, preferably 0.03 mg/kg to less than 1.0 mg/kg of inhibitor.

5 The pharmaceutical compositions preferably are constituted so that they can be administered parenterally or orally. Solutions of the active compounds as free bases and free acids or
10 pharmaceutically acceptable salts can be prepared in water suitable mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions
15 of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or
20 dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of the microorganisms such as
25 bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The
30 proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion,

WO 95/19970

PCT/US95/00911

-105-

and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, paragens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferred to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions of agents delaying absorption, for example, gelatin.

10 Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients, into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of the sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yields a powder of active ingredients plus an additional desired ingredient from a previously sterile-filtered solution thereof.

25 As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the

WO 95/19970

PCT/US95/00911

-106-

therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

5 It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined
10 quantity of active materials calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique
15 characteristics of the active materials and the particular therapeutic effect to be achieved, and (b) the limitation inherent in the art of compounding such active materials for the treatment of disease in living subjects having a diseased condition in which bodily
20 health is impaired as herein disclosed in detail.

The principal active ingredients are compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore
25 disclosed. A unit parenteral dosage form can, for example, contain the principal active compound, i.e. an inhibitor, in amounts ranging from about 0.5 to about 100 mg, with from about 0.1 to 50 mg being preferred. The daily parenteral doses for mammalian subjects to be
30 treated ranges from 0.01 mg/kg to 10 mg/kg of the inhibitor. The preferred daily dosage range is 0.1 mg/kg to 1.0 mg/kg.

WO 95/19970

PCT/US95/00911

-107-

For oral dosages, the daily amount may range from 0.01 mg of active compound/kg of mammalian subject to 100 mg/kg, preferably 0.1 to 10 mg/kg of subject.

5 The inhibitor described above may form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc. References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent
10 compound and hydrates thereof.

The active compounds described herein are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present
15 invention.

Pharmaceutically acceptable acid addition salts of the active compounds include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic,
20 hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and
25 aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate,
30 propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate,

WO 95/19970

PCT/US95/00911

-108-

mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also
5 contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge, S.M. et al, "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, 66, pp. 1-19 (1977)).

The acid addition salts of said basic
10 compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. Preferably, an active compound can be converted to an acidic salt by treating with an aqueous solution of the desired acid,
15 such that the resulting pH is less than 4. The solution can be passed through a C18 cartridge to absorb the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile, and the like, and
20 isolated by concentrating under reduced pressure followed by lyophilization. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms
25 somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

Pharmaceutically acceptable base addition
30 salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium,

WO 95/19970

PCT/US95/00911

-109-

magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, 5 for example, Berge, S.M. et al, "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, 66, pp. 1-19 (1977)).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce 10 the salt in the conventional manner. Preferably, an active compound can be converted to a base salt by treating with an aqueous solution of the desired base, such that the resulting pH is greater than 9. The solution can be passed through a C18 cartridge to absorb 15 the compound, washed with copious amounts of water, the compound eluted with a polar organic solvent such as, for example, methanol, acetonitrile and the like, and isolated by concentrating under reduced pressure followed by lyophilization. The free acid form may be 20 regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts 25 are equivalent to their respective free acids for purposes of the present invention.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, 30 the solvated forms, including hydrated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

WO 95/19970

PCT/US95/00911

-110-




Certain of the compounds of the present invention possess one or more chiral centers and such center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric
5 forms as well as the appropriate mixtures thereof.

While the forms of the invention herein constitute presently preferred embodiments, many others are possible. It is not intended herein to mention all of the possible equivalent forms or ramifications of the
10 invention. It is understood that the terms used herein are merely descriptive rather than limiting and that various changes may be made without departing from the spirit or scope of the invention.

WO 95/19970

PCT/US95/00911

-111-


Scheme 1. Synthesis of Preferred Group 1.Scheme 2. Synthesis of Preferred Group 4: [3,2-g] ring fusion.Scheme 3. Synthesis of Preferred Group 5: [4,5-g] ring fusion.

SUBSTITUTE SHEET (RULE 26)


WO 95/19970

PCT/US95/00911


-112-



Scheme 4. Synthesis of Preferred Group 5: [5.4-g] ring fusion.



Scheme 5. Synthesis of Preferred Group 6: [4.5-g] ring fusion.






Scheme 6. Synthesis of Preferred Group 6: 5.4-g] ring fusion.

WO 95/19970

PCT/US95/00911

-113-




Scheme 7. Synthesis of Preferred Group 7.Scheme 8. Synthesis of Preferred Group 10: [4,3-g] ring fusion.Scheme 9. Synthesis of Preferred Group 10: [3,4-g] ring fusion.

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911


-114-

Scheme 10. Synthesis of Preferred Group 11.Scheme 11. Synthesis of Preferred Group 13: A & E are Nitrogen.Scheme 12. Synthesis of Preferred Group 13: B & E are Nitrogen.


WO 95/19970

PCT/US95/00911


-115-



Scheme 13. Synthesis of Preferred Group 33: [4,5-f] ring fusion



Scheme 14. Synthesis of Preferred Group 33: [4,5-h] ring fusion






Scheme 15. Synthesis of Preferred Group 39: [3,2-d] ring fusion

WO 95/19970

PCT/US95/00911




-116-

Scheme 16. Synthesis of Preferred Group 39: [3,2-d] ring fusionScheme 17. Synthesis of Preferred Group 39: [2,3-d] ring fusionScheme 18. Synthesis of Preferred Group 41: [3',2':2,3][4,5-d] ring fusion

WO 95/19970

PCT/US95/00911

-117-





Scheme 19. Synthesis of Preferred Group 41: [2,3':2,3][5,4-d] ring fusionScheme 20. Synthesis of Preferred Group 44: [4',5':2,3][4,5-d] ring fusionScheme 21. Synthesis of Preferred Group 45: [4',5':2,3][4,5-d] ring fusion

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-118-

Scheme 22. Synthesis of Preferred Group 49: [2',3':2,3][4,5-d] ring fusionScheme 23. Synthesis of Preferred Group 50: [3,2-d] ring fusionScheme 24. Synthesis of Preferred Group 50: [2,3-d] ring fusionScheme 25. Synthesis of Preferred Group 61: [3,2-d] ring fusion

SUBSTITUTE SHEET (RULE 26)


WO 95/19970

PCT/US95/00911

-119-

What Is Claimed Is:

1. A method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof,
 5 a compound of the formula:



- wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or
 2) one of Y and Z is C=C, C=N, whereupon the other one
 10 of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure
 15 is a fused 6,5 (5 or 6) tricycle;

- A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five
 20 membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

WO 95/19970

PCT/US95/00911

-120-

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

5 n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom, and both R and S stereocentres on either linker are included;

10 R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono
15 or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms),
20 thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms),
25 lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and
m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl,
30 benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms),

WO 95/19970

PCT/US95/00911

-121-

cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N- and/or N'- mono- or di lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, N- and/or O- mono- or di lower alkylhydroxylamino (1-4 carbon atoms), or any two substituents on contiguous carbon atoms taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranlyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R' and R¹ can be independently as appropriate, not present, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

WO 95/19970

PCT/US95/00911

-122-


R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create
5 chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

or a pharmaceutical salt or hydrate thereof.

2. The method of claim 1 wherein n = 0, A-E,
10 Y & Z being carbon, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen.

3. The method of claim 2 having the ring structure:




4. The method of claim 1 wherein n = 0 or 1,
15 with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

5. The method of claim 4 having the ring
20 structure:

WO 95/19970

PCT/US95/00911


-123-



6. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen.

7. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or lower alkyl if on nitrogen.

8. The method of claim 7 having the ring structure:



9. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, Y and Z both carbon, X = NH, Ar a benzene ring, optionally

WO 95/19970


PCT/US95/00911

-124-

substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

10. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

11. The method of claim 10 having the ring structure:



12. The method of claim 1 wherein $n = 0$ or 1, A & B taken together, and E as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or lower alkyl if on nitrogen, or a lone pair of electrons.

13. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, Y and Z both carbon, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

WO 95/19970


PCT/US95/00911

-125-

14. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, Y and Z both carbon, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

15. The method of claim 1 wherein $n = 0$ or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, Y and Z both carbon, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

16. The method of claim 15 having the ring structure:



17. The method of claim 1 wherein $n = 0$, A & B taken together, with D & E taken separately, all as nitrogen, Y and Z both carbon, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or lower alkyl if on nitrogen, or a lone pair of electrons.

18. The method of claim 1 wherein $n = 0$ or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, along with Y and Z, X = NH, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

WO 95/19970


PCT/US95/00911

-126-

19. The method of claim 1 wherein $n = 0$, with any two of A, B, D or E as nitrogen, the remaining two being carbon, along with Y and Z, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

20. The method of claim 1 wherein $n = 0$, A-E, and one of Y and Z being carbon, the other nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons

21. The method of claim 20 having the ring structure:




22. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

23. The method of claim 22 having the ring structure:

WO 95/19970

PCT/US95/00911

-127-



24. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A & B or D & E taken together as sulfur,
the remaining pair both being carbon, along with one of
Y and Z, the other being nitrogen, $X = \text{NH}$, Ar a benzene
ring, optionally substituted, and R^5 - R^8 hydrogen or a
lone pair of electrons.

25. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A & B or D & E taken together as nitrogen,
the remaining pair both being carbon, along with one of
Y and Z, the other being nitrogen, $X = \text{NH}$, Ar a benzene
ring, optionally substituted, and R^5 - R^8 hydrogen, or
optionally lower alkyl if on nitrogen in the pyrrole
ring, or a lone pair of electrons.


26. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as oxygen, and E as nitrogen, or D
& E taken together as oxygen and A as nitrogen, one of
Y and Z being carbon the other nitrogen, $X = \text{NH}$, Ar a
benzene ring, optionally substituted, and R^5 - R^8 hydrogen
or a lone pair of electrons.

27. The method of claim 26 having the ring
structure:

WO 95/19970

PCT/US95/00911

-128-



28. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as sulfur, and E as nitrogen, or D
& E taken together as sulfur and A as nitrogen, one of
Y and Z being carbon the other nitrogen, $X = \text{NH}$, Ar a
5 benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen
or a lone pair of electrons.

29. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together, and E as nitrogen, one of Y and Z
being carbon the other nitrogen, $X = \text{NH}$, Ar a benzene
10 ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen or
optionally lower alkyl if on nitrogen or a lone pair of
electrons.

30. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as oxygen, and D as nitrogen, or D
15 & E taken together as oxygen and B as nitrogen, one of
Y and Z being carbon the other nitrogen, $X = \text{NH}$, Ar a
benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen,
lower alkyl, or a lone pair of electrons.

31. The method of claim 1 wherein $n = 0$ or 1 ,
20 A & B taken together as sulfur, and D as nitrogen, or D
& E taken together as sulfur and B as nitrogen, one of
Y and Z being carbon the other nitrogen, $X = \text{NH}$, Ar a
benzene ring, optionally substituted, and $\text{R}^5\text{-R}^8$ hydrogen,
lower alkyl, or a lone pair of electrons.

WO 95/19970


PCT/US95/00911

-129-

32. The method of claim 1 wherein $n = 0$ or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one of Y and Z being carbon the other nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

33. The method of claim 1 wherein $n = 0$ or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

34. The method of claim 33 having the ring structure:



35. The method of claim 1 wherein $n = 0$, with any two of A, B, D or E as nitrogen, the remaining two being carbon, along with one of Y and Z, the other being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

36. The method of claim 1 wherein $n = 0$, A-E carbon, Y and Z nitrogen, $X = NH$, Ar a benzene ring,


WO 95/19970

PCT/US95/00911

-130-


optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

37. The method of claim 36 having the ring structure:



5 38. The method of claim 1 wherein $n = 0$ or 1, A-E being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen.

10 39. The method of claim 38 having the ring structure:



40. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally

WO 95/19970

PCT/US95/00911

-131-

substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

41. The method of claim 1 wherein n = 0 or 1, with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

42. The method of claim 1 wherein n = 0 or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or lower alkyl if on nitrogen.

43. The method of claim 1 wherein n = 0 or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

44. The method of claim 1 wherein n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

45. The method of claim 1 wherein n = 0, A & B taken together, and E as nitrogen, one of Y & Z being ethylidene, X = NH, Ar a benzene ring, optionally


WO 95/19970

PCT/US95/00911

-132-

substituted, and R^5 - R^8 hydrogen or lower alkyl if on nitrogen or a lone pair of electrons.

46. The method of claim 44 having the ring structure:



5 47. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as oxygen, and D as nitrogen, or D
& E taken together as oxygen and B as nitrogen, one of
Y & Z being ethylidene, $X = NH$, Ar a benzene ring,
optionally substituted, and R^5 - R^8 hydrogen, lower alkyl,
10 or a lone pair of electrons.


 48. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as sulfur, and D as nitrogen, or D
& E taken together as sulfur and B as nitrogen, one of
Y & Z being ethylidene, $X = NH$, Ar a benzene ring,
15 optionally substituted, and R^5 - R^8 hydrogen, lower alkyl,
or a lone pair of electrons.

 49. The method of claim 48 having the ring
structure:

WO 95/19970

PCT/US95/00911

-133-



50. The method of claim 1 wherein $n = 0$ or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

51. The method of claim 1 wherein $n = 0$ or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

52. The method of claim 1 wherein $n = 0$, with any two of A, B, D or E as nitrogen, the remaining two being carbon, one of Y & Z being ethylidene, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.


53. The method of claim 1 wherein $n = 0$ or 1, A-E being carbon, one of Y & Z being sulfur, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

WO 95/19970

PCT/US95/00911

-134-

54. The method of claim 53 having the ring structure:



55. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

56. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

57. The method of claim 1 wherein $n = 0$ or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair or lower alkyl if on nitrogen.

58. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of

WO 95/19970


PCT/US95/00911

-135-

Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

5 59. The method of claim 1 wherein n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair of electrons.

10 60. The method of claim 59 having the ring structure:



15 61. The method of claim 1 wherein n = 0, A & B taken together, and E as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or lower alkyl if on nitrogen or a lone pair of electrons.

20 62. The method of claim 1 wherein n = 0 or 1, A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being sulfur, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen, lower alkyl, or a lone pair of electrons.

WO 95/19970

PCT/US95/00911

-136-

63. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as sulfur, and D as nitrogen, or D
& E taken together as sulfur and B as nitrogen, one of
Y & Z being sulfur, $X = NH$, Ar a benzene ring,
5 optionally substituted, and R^5 - R^8 hydrogen, lower alkyl,
or a lone pair of electrons.

64. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together, and D as nitrogen, or D & E taken
together, and B as nitrogen, one of Y & Z being sulfur,
10 $X = NH$, Ar a benzene ring, optionally substituted, and
 R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

65. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A, B, D or E as nitrogen, the remaining
three being carbon, one of Y & Z being sulfur, $X = NH$,
15 Ar a benzene ring, optionally substituted, and R^5 - R^8
hydrogen or a lone pair of electrons.

66. The method of claim 1 wherein $n = 0$ or 1 ,
A-E being carbon, one of Y & Z being nitrogen, $X = NH$,
Ar a benzene ring, optionally substituted, and R^5 - R^8
20 hydrogen, or lower alkyl if on nitrogen.

67. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A & B or D & E taken together as oxygen,
the remaining pair both being carbon, one of Y & Z being
nitrogen, $X = NH$, Ar a benzene ring, optionally
25 substituted, and R^5 - R^8 hydrogen or a lone pair or lower
alkyl if on nitrogen.

68. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A & B or D & E taken together as sulfur,
the remaining pair both being carbon, one of Y & Z being

WO 95/19970

PCT/US95/00911


-137-

nitrogen, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair or lower alkyl if on nitrogen.

5 69. The method of claim 1 wherein n = 0 or 1, with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or lower alkyl if on nitrogen.

10 70. The method of claim 1 wherein n = 0 or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair
15 or lower alkyl if on nitrogen.

71. The method of claim 70 having the ring structure:



20 72. The method of claim 1 wherein n = 0 or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being nitrogen, X = NH, Ar a benzene ring, optionally substituted, and R⁵-R⁸ hydrogen or a lone pair where appropriate, or lower alkyl if on nitrogen.

WO 95/19970

PCT/US95/00911

-138-

73. The method of claim 1 wherein $n = 0$, A & B taken together, and E as nitrogen, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or lower alkyl if on
5 nitrogen or a lone pair of electrons.

74. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as oxygen, and D as nitrogen, or D & E taken together as oxygen and B as nitrogen, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring,
10 optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

75. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as sulfur, and D as nitrogen, or D & E taken together as sulfur and B as nitrogen, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring,
15 optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.

76. The method of claim 1 wherein $n = 0$ or 1, A & B taken together, and D as nitrogen, or D & E taken together, and B as nitrogen, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons where appropriate.
20

77. The method of claim 1 wherein $n = 0$ or 1, with one of A, B, D or E as nitrogen, the remaining three being carbon, one of Y & Z being nitrogen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.
25


WO 95/19970

PCT/US95/00911

-139-

78. The method of claim 1 wherein $n = 0$ or 1 , A-E being carbon, one of Y & Z being oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

5 79. The method of claim 78 having the ring structure:



80. The method of claim 1 wherein $n = 0$ or 1 , with one of A & B or D & E taken together as oxygen, the remaining pair both being carbon, one of Y & Z being
10 oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

81. The method of claim 1 wherein $n = 0$ or 1 , with one of A & B or D & E taken together as sulfur, the remaining pair both being carbon, one of Y & Z being
15 oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

82. The method of claim 1 wherein $n = 0$ or 1 , with one of A & B or D & E taken together as nitrogen, the remaining pair both being carbon, one of Y & Z being
20 oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of

WO 95/19970

PCT/US95/00911


-140-

electrons where appropriate or lower alkyl if on nitrogen.

83. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as oxygen, and E as nitrogen, or D & E taken together as oxygen and A as nitrogen, one of Y & Z being oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

84. The method of claim 1 wherein $n = 0$ or 1, A & B taken together as sulfur, and E as nitrogen, or D & E taken together as sulfur and A as nitrogen, one of Y & Z being oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or a lone pair of electrons.

85. The method of claim 84 having the ring structure:



86. The method of claim 1 wherein $n = 0$, A & B taken together, and E as nitrogen, one of Y & Z being oxygen, $X = NH$, Ar a benzene ring, optionally substituted, and R^5 - R^8 hydrogen or optionally lower alkyl if on nitrogen or a lone pair of electrons.

WO 95/19970

PCT/US95/00911

-141-

87. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as oxygen, and D as nitrogen, or D
& E taken together as oxygen and B as nitrogen, one of
Y & Z being oxygen, $X = NH$, Ar a benzene ring,
5 optionally substituted, and R^5 - R^8 hydrogen, lower alkyl,
or a lone pair of electrons.

88. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together as sulfur, and D as nitrogen, or D
& E taken together as sulfur and B as nitrogen, one of
10 Y & Z being oxygen, $X = NH$, Ar a benzene ring,
optionally substituted, and R^5 - R^8 hydrogen, lower alkyl,
or a lone pair of electrons.

89. The method of claim 1 wherein $n = 0$ or 1 ,
A & B taken together, and D as nitrogen, or D & E taken
15 together, and B as nitrogen, one of Y & Z being oxygen,
 $X = NH$, Ar a benzene ring, optionally substituted, and
 R^5 - R^8 hydrogen, lower alkyl, or a lone pair of electrons.

90. The method of claim 1 wherein $n = 0$ or 1 ,
with one of A, B, D or E as nitrogen, the remaining
20 three being carbon, one of Y & Z being oxygen, $X = NH$,
Ar a benzene ring, optionally substituted, and R^5 - R^8
hydrogen or a lone pair of electrons.

91. The method of claim 1 wherein any of the
substituents R^1 , R^2 , R^3 or R^4 contain chiral centers, or
25 in the case of R^2 create chiral centers on the linking
atoms, then all stereoisomers thereof both separately
and as racemic and/or diastereoisomeric mixtures are
included therein.


WO 95/19970

PCT/US95/00911

-142-

92. The method of claim 1 wherein the compound is selected from the group consisting of 4-(3-Bromoanilino)benzo[g]quinazoline; 4-([R]-1-Phenylethylamino)benzo[g]quinazoline; 4-(3-Bromoanilino)pyrrolo[3,2-g]quinazoline; 4-(3-Bromoanilino)thiazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)oxazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)imidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)triazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)-6N-methylimidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)-8N-methylimidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)pyrazolo[2,3-g]quinazoline; 4-(3-Bromoanilino)imidazolo[4,5-h]quinazoline; 4-(3-Bromoanilino)benzothieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)-8-nitrobenzothieno[3,2-d]pyrimidine; 8-Amino-4-(3-bromoanilino)benzothieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)-8-methoxybenzothieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)thiazolo[4':5':4,5]thieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)indolo[3,2-d]pyrimidine; 4-(3-Bromoanilino)indolo[2,3-d]pyrimidine.

93. A compound of the formula:



where:

- wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or

WO 95/19970

PCT/US95/00911

-143-

2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom, and both R and S stereocentres on either linker are included;

R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-144-

- carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxy carbonyl (1-4 carbon atoms), cycloalkoxy carbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and
- m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;
- R³, R⁴, R⁵ and R⁶ are independently not present,
- H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;
- or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);
- lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused

WO 95/19970

PCT/US95/00911

-145-

pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁶ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

with the proviso that the ring containing A-E is aromatic;

and with the proviso that if A and B taken together and E are nitrogen, and if neither Y nor Z is a heteroatom, and if X = NH, and n = 1, and R¹ = H and Ar = Ph, then one of the imidazole nitrogen atoms must have a substituent from the R³-R⁶ group other than lone pair or hydrogen;

and with the proviso that if A-E are carbon, and Y is a bond, and Z is sulfur, and X = NH, and n = 0, then Ar cannot be unsubstituted phenyl, unsubstituted or substituted pyridyl or unsubstituted or substituted pyrimidyl;

WO 95/19970

PCT/US95/00911

-146-

or a pharmaceutical salt or hydrate thereof.

94. The compound of claim 93 having the further provisos:

5 that if A-E are carbon, Y and Z cannot be both carbon or one ethylidene and the other a bond, unless at least one of R³-R⁶ is not hydrogen; and

that if A-E are carbon one of Y and Z cannot be nitrogen, substituted with hydrogen, and the other a bond.

10 95. The compound of claim 2 wherein the compound is selected from the group consisting of 4-(3-Bromoanilino)pyrrolo[3,2-g]quinazoline; 4-(3-Bromoanilino)thiazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)oxazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)imidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)triazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)-6N-methylimidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)-8N-methylimidazolo[4,5-g]quinazoline; 4-(3-Bromoanilino)pyrazolo[2,3-g]quinazoline; 4-(3-Bromoanilino)imidazolo[4,5-h]quinazoline; 4-(3-Bromoanilino)benzothieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)-8-nitrobenzothieno[3,2-d]pyrimidine; 8-Amino-4-(3-bromoanilino)benzothieno[3,2-d]pyrimidine; 4-(3-Bromoanilino)-8-methoxybenzothieno[3,2-d]pyrimidine; 25 4-(3-Bromoanilino)thiazolo[4'5':4,5]thieno[3,2-d]pyrimidine.


96. A method of inhibiting Erb-B2 or Erb-B3 or Erb-B4 receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, 30 a compound of the formula:

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-147-



wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

WO 95/19970

PCT/US95/00911

-148-

if $n = 2$, R^1 can be independently H or lower alkyl on either linking carbon atom, and both R and S stereocentres on either linker are included;

R^2 is lower alkyl (1-4 carbon atoms),
5 cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; $-O-C(O)-R$), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or
10 dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; $-C(O)R$), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl
15 (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R^2 taken
20 together can form a carbocyclic ring of 5-7 members; and
 $m = 0-3$, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and
25 quinazolinyl;

R^3 , R^4 , R^5 and R^6 are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy
30 (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato ($-OC(O)OR$)

WO 95/19970

PCT/US95/00911

-149-

where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by
5 mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms),
10 hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;
15

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of
20 the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

25 if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

30 if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all


WO 95/19970

PCT/US95/00911

-150-

stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

97. A pharmaceutical composition adapted for administration as an inhibitor of the epidermal growth factor receptor family of tyrosine kinases, comprising a therapeutically effective amount of a compound of the following structure in admixture with a pharmaceutically acceptable excipient, diluent or carrier:



- wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;
- A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-151-

either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl on either linking carbon atom, and both R and S stereocentres on either linker are included;

R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and

m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

WO 95/19970

PCT/US95/00911

-152-

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

WO 95/19970

PCT/US95/00911

-153-


if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms),
5 amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic
10 and/or diastereoisomeric mixtures are included;

or a pharmaceutical salt or hydrate thereof.

98. A method of treating cancer by treating, with an effective cancer inhibiting amount, a mammal, in need thereof, a compound of the formula:



15 wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or
2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic
20 rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

WO 95/19970

PCT/US95/00911

-154-

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five
5 membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

10 X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

15 if n = 2, R¹ can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom, and both R and S stereocentres on either linker are included;

20 R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or
25 dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl
30 (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-155-

together can form a carbocyclic ring of 5-7 members; and

m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinoliny, isoquinoliny and quinazolinyl;

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can

WO 95/19970


PCT/US95/00911

-156-

be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

- 5 if one or two of A through E are N, then if any of R^3 - R^6 is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and R^{10} is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);
- 10 if any of the substituents R^1 , R^2 , R^3 or R^4 contain chiral centers, or in the case of R^1 create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;
- 15 or a pharmaceutical salt or hydrate thereof.

99. A method of treating psoriasis by treating, with an effective psoriasis inhibiting amount, a mammal, in need thereof, a compound of the formula:



- wherein: 1) Y and Z are both C (carbon), both
 20 N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or
 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or
 25 6) tricycle, or 3) one of Y and Z is N, O or S,

WO 95/19970

PCT/US95/00911

-157-

whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

5 A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be
10 either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon
15 atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl on either linking carbon atom, and both R and S
20 stereocentres on either linker are included;

R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower
25 acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4
30 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-158-

alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and

m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-159-

any lower alkyl group substituent on any of the substituents in R^3 - R^8 which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;


if one or two of A through E are N, then if any of R^3 - R^6 is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R^{10} is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R^1 , R^2 , R^3 or R^4 contain chiral centers, or in the case of R^1 create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

or a pharmaceutical salt or hydrate thereof.

100. A method of preventing blastocyte implantation by treating, with an effective blastocyte implantation inhibiting amount, a mammal, in need thereof, a compound of the formula:



wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-160-

of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond
5 between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E
10 can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are
15 all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

20 n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl on either linking carbon atom, and both R and S stereocentres on either linker are included;

R² is lower alkyl (1-4 carbon atoms),
25 cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or
30 dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl

WO 95/19970

PCT/US95/00911

-161-

(3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and
m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

WO 95/19970

PCT/US95/00911

-162-

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

5 any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidiny, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;


10 if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

15 if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

20 or a pharmaceutical salt or hydrate thereof.

101. A contraceptive composition comprising a contraceptively effective amount of a compound of the following formula in admixture with a contraceptively acceptable excipient, diluent or carrier:



SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-163-

wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N; whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl on either linking carbon atom, and both R and S stereocentres on either linker are included;

R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl,

WO 95/19970

PCT/US95/00911

-164-

lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and

m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon

WO 95/19970

PCT/US95/00911

-165-

atoms), or taken together can be methylene-, ethylene- or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

5 R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can
10 be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

if one or two of A through E are N, then if
15 any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴
20 contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

or a pharmaceutical salt or hydrate thereof.


25 102. A method of treating pancreatitis by treating, with an effective amount inhibiting a mammal, in need thereof, a compound of the formula:

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-166-



wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

R¹ = H or lower alkyl;

n = 0, 1 or 2;

if n = 2, R¹ can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom,

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-167-

and both R and S stereocentres on either linker are included;

5 R² is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; -O-C(O)-R), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; -C(O)R), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R² taken together can form a carbocyclic ring of 5-7 members; and

20 m = 0-3, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

25 R³, R⁴, R⁵ and R⁶ are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

30

WO 95/19970

PCT/US95/00911

-168-

or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

5 lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene-
10 or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate,
15 lone pairs of electrons, H, or lower alkyl (1-4 carbon atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy,
20 amino, lower monoalkylamino, lower dialkylamino, N-pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N
25 atoms, that substituent cannot be either OH or SH; and

R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create
30 chiral centers on the linking atoms, then all stereoisomers thereof both separately and as racemic and/or diastereoisomeric mixtures are included;

or a pharmaceutical salt or hydrate thereof.


SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-169-

103. A method of treating kidney disease by treating, with an effective kidney disease inhibiting amount, a mammal, in need thereof, a compound of the formula:



5 wherein: 1) Y and Z are both C (carbon), both N or one N and the other C, in which case the ring structure is a linearly fused 6,6 (5 or 6) tricycle, or 2) one of Y and Z is C=C, C=N, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a nonlinear 6,6 (5 or 6) tricycle, or 3) one of Y and Z is N, O or S, whereupon the other one of Y or Z is simply a bond between the two aromatic rings, then the ring structure is a fused 6,5 (5 or 6) tricycle;

15 A, B, D and E can all be carbon, or up to two of them can be nitrogen, whereupon the remaining atoms must be carbon, or any two contiguous positions in A-E can be a single heteroatom, N, O or S, forming a five membered fused ring, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen, except that the case where A and B taken together, and D and E taken separately are all three nitrogen atoms;

25 X = O, S, NH or NR⁹, such that R⁹ = lower alkyl (1-4 carbon atoms), OH, NH₂, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms);

WO 95/19970

PCT/US95/00911

-170-

 $R^1 = \text{H or lower alkyl};$ $n = 0, 1 \text{ or } 2;$

if $n = 2$, R^1 can be independently H or lower alkyl (1-4 carbon atoms) on either linking carbon atom, and both R and S stereocentres on either linker are included;

R^2 is lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), nitro, halo, lower perfluoroalkyl (1-4 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms; $-\text{O}-\text{C}(\text{O})-\text{R}$), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8 carbon atoms), hydroxymethyl, lower acyl (1-4 carbon atoms; $-\text{C}(\text{O})\text{R}$), cyano, lower thioalkyl (1-4 carbon atoms), lower sulfinylalkyl (1-4 carbon atoms), lower sulfonylalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), sulfinylcycloalkyl (3-8 carbon atoms), sulfonylcycloalkyl (3-8 carbon atoms), mercapto, lower alkoxycarbonyl (1-4 carbon atoms), cycloalkoxycarbonyl (3-8 carbon atoms), lower alkenyl (2-4 carbon atoms), cycloalkenyl (4-8 carbon atoms), lower alkynyl (2-4 carbon atoms), or two R^2 taken together can form a carbocyclic ring of 5-7 members; and $m = 0-3$, wherein Ar is phenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazolyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl and quinazolinyl;

R^3, R^4, R^5 and R^6 are independently not present, H, lower alkyl (1-4 carbon atoms), cycloalkyl (3-8 carbon atoms), lower alkoxy (1-4 carbon atoms), cycloalkoxy (3-8 carbon atoms), hydroxy, lower acyloxy (1-4 carbon atoms), amino, lower mono or dialkylamino (1-4 carbon atoms), lower mono or dicycloalkylamino (3-8

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-171-

carbon atoms), lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms), carbonato (-OC(O)OR) where R is alkyl of from 1-4 carbon atoms or cycloalkyl of from 3-8 carbon atoms;

5 or ureido or thioureido or N- or O- linked urethane any one of which is optionally substituted by mono or di-lower alkyl (1-4 carbon atoms) or cycloalkyl (3-8 carbon atoms);

10 lower thioalkyl (1-4 carbon atoms), thiocycloalkyl (3-8 carbon atoms), mercapto, lower alkenyl (2-4 carbon atoms), hydrazino, N'-lower alkylhydrazino (1-4 carbon atoms), lower acylamino (1-4 carbon atoms), hydroxylamino, lower O-alkylhydroxylamino (1-4 carbon atoms), or taken together can be methylene-, ethylene-
15 or propylenedioxy, or taken together form a fused pyrrolidine, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholino or thiomorpholino ring;

R⁷ and R⁸ can be independently as appropriate, lone pairs of electrons, H, or lower alkyl (1-4 carbon
20 atoms);

any lower alkyl group substituent on any of the substituents in R³-R⁸ which contain such a moiety can be optionally substituted with one or more of hydroxy, amino, lower monoalkylamino, lower dialkylamino, N-
25 pyrrolidyl, N-piperidinyl, N-pyridinium, N-morpholino, N-thiomorpholino or N-piperazino groups;

if one or two of A through E are N, then if any of R³-R⁶ is on a neighboring C atom to one of the N atoms, that substituent cannot be either OH or SH; and

30 R¹⁰ is H or lower alkyl (1-4 carbon atoms), amino or lower mono- or dialkylamino (1-4 carbon atoms);

if any of the substituents R¹, R², R³ or R⁴ contain chiral centers, or in the case of R¹ create chiral centers on the linking atoms, then all

SUBSTITUTE SHEET (RULE 26)

WO 95/19970

PCT/US95/00911

-172-

stereoisomers thereof both separately and as racemic
and/or diastereoisomeric mixtures are included;
or a pharmaceutical salt or hydrate thereof.

WO 95/19970

PCT/US95/00911

1 / 9




FIG. 1

WO 95/19970

PCT/US95/00911

2 / 9




FIG. 2

WO 95/19970

PCT/US95/00911

3 / 9




FIG. 3

WO 95/19970

PCT/US95/00911

4 / 9




FIG. 4

WO 95/19970

PCT/US95/00911

5 / 9




FIG. 5

WO 95/19970

PCT/US95/00911

6 / 9




FIG. 6

WO 95/19970

PCT/US95/00911

7 / 9




FIG. 7

WO 95/19970

PCT/US95/00911

8 / 9




FIG. 8

WO 95/19970

PCT/US95/00911

9 / 9




FIG. 9

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/00911

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/70 A61K31/505 C07D487/04 C07D513/04 C07D498/04
C07D495/04 C07D513/14 C07D495/14 C07D491/048 A61K31/495
/(C07D487/04, 239:00, 209:00), (C07D513/04, 277:00, 239:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 566 226 (ZENECA) 20 October 1993 see page 20, line 11 - page 21, line 30; claim 1	1
X	MONATSCHEFTE FUR CHEMIE, vol. 96, 1965 WIEN AT, pages 542-547, W. DYMEK ET AL. 'Darstellung und Umwandlungen von 4-Anilino-1,2-dihydro-7,8-benzochinazolon- (2)' see pages 543 and 547, compound X	93

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 May 1995

Date of mailing of the international search report

23.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Internatic Application No
PCT/US 95/00911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, 1974 LETCHWORTH GB, pages 1970-1975, R.G.R. BACON ET AL. 'Metal ions and complexes in organic reactions. Part XVIII. Structural variations in the production of polycyclic heterocyclic systems by iron-(II)-promoted cyclisations of nitro-substituted precursors' see pages 1971 and 1974, compound 11 ---	93
X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, 1992 LETCHWORTH GB, pages 2789-2811, A.H.M. AL-SHAAR ET AL. 'The synthesis of heterocycles via addition-elimination reactions of 4- and 5-amino imidazoles' see pages 2793, 2809 and 2810, compounds 55c, 55e and 55f. ---	93
X	CHEMICAL ABSTRACTS, vol. 106, no. 11, 1987 Columbus, Ohio, US; abstract no. 84629e, HOECHST INDIA 'Pharmacologically active pyrimido[4,5-b]indoles and their salts' page 614; see abstract and 12th Collective Index, Chem.Subst., page 80797, column 3, lines 3,11,38,41,47 & IN,A,157 280 (HOECHST) 22 February 1986 ---	93
X	CHEMICAL ABSTRACTS, vol. 94, no. 17, 1981 Columbus, Ohio, US; abstract no. 139732z, T. HIGASHINO ET AL. 'Triazolo[4,5-d]pyrimidines VII. The photochemical transformation of 3-phenyl-3H-1,2,3-triazolo[4,5-d] pyrimidines into 9H-pyrimido[4,5-b]indoles' page 758; see abstract & HETEROCYCLES, vol. 15, no. 1, 1981 pages 483-487, ---	93

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 95/00911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ARCHIV DER PHARMAZIE, vol. 326, no. 11, 1993 WEINHEIM DE, pages 879-885, A. MONGE ET AL. 'New 4-amino-7,8-dimethoxy-5H-pyrimido[5,4-b]in dole derivatives: Synthesis and studies as inhibitors of phosphodiesterase' see scheme 1, compounds 6a, 6d, 6f, 6h, 6i, 6j</p> <p>---</p>	93
X	<p>TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 48, no. 36, 1992 OXFORD GB, pages 7689-7702, S. ATHMANI ET AL. 'Azoles. Part 10. Thiazolo[4',5';4,5]thieno[3,2-d]pyrimidine , a new heterocyclic ring system' see pages 7690 and 7696, compounds 5,6,10 and 11</p> <p>---</p>	93
X	<p>CHEMICAL ABSTRACTS, vol. 113, no. 7, 1990 Columbus, Ohio, US; abstract no. 59093n, KH.M. HASSAN ET AL. 'Some reactions of 3-amino-2-(carboethoxy)-4,6-dimethylthieno [2,3-b]pyridine. Synthesis of some new thienopyridopyrimidines' page 698; see abstract & PHOSPHORUS, SULFUR SILICON RELAT. ELEM. 1990, 47(3-4), 283-9,</p> <p>---</p>	93
X	<p>CHEMICAL ABSTRACTS, vol. 92, no. 17, 1980 Columbus, Ohio, US; abstract no. 146648p, V.I. SHVEDOV ET AL. 'Studies of thieno and pyridothienopyrimidines. 3. Transformations of 7,9-dimethyl- and 7,9-dimethyl-8-nitropyrido[3'2':4,5]thieno [3,2-d]pyrimidin-4-ones' page 580; see compound V & KHIM. GETEROTSIKL. SOEDIN. 1979, (10), 1340 - 2,</p> <p>---</p> <p>-/--</p>	93

INTERNATIONAL SEARCH REPORT

Internat. Application No
PCT/US 95/00911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 86, no. 23, 1977 Columbus, Ohio, US; abstract no. 171368f, S. SANGAPURE ET AL. 'Studies in benzofurans: Part I. Synthesis of some benzofuro[3,2-d]pyrimidine derivatives' page 549; see abstract & INDIAN J. CHEM. B 1976, 14B(9), 688-91, ---	93
X	CHEMICAL ABSTRACTS, vol. 114, no. 17, 1991 Columbus, Ohio, US; abstract no. 164140u, A.V. KADUSHKIN ET AL. 'Condensed pyrrolo[3,2-d]pyrimidines : synthesis and biological activity' page 769; 12th Collective Index, Chem. Subst., p. 80797, c. 3, l. 61-65; p. 80798, c. 3, l. 43,57,59,65 & KHIM.-FARM. ZH. 1990, 24(12),18-22, ---	93
X	JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 17,no. 198, 1980 PROVO US, pages 923-928, M. ROBBA ET AL. '[1]Benzothienopyrimidines. I. Etude de la 3H-benzothieno[3,2-d]pyrimidone-4' see compounds 9,17 and 19 ---	93
X	INDIAN JOURNAL OF CHEMISTRY, SECTION B, vol. 16B,no. 7, 1978 NEW DELHI, INDIA, pages 627-629, S.S. SANGAPURE ET AL. 'Studies in benzofurans : Part III- Synthesis & reactions of 2-alkyl- or 2-aryl-3,4-dihydr-4-oxobenzofuro[3,2-d]pyrimidines & 4-thioanalogues' see compounds VIIc,d,e; VIIId,e,f; IXa ---	93
X	INDIAN JOURNAL OF CHEMISTRY, SECTION B, vol. 15B,no. 5, 1977 NEW DELHI, INDIA, pages 485-487, S.S. SANGAPURE ET AL. 'Studies in benzofurans: Part II. Nucleophilic displacement reactions of 4-chlorobenzofuro[3,2-d]pyrimidine' see compounds IIe,i,j,k,l,m,n,o; IIIa,b,c,d,e,f,g,h,i; IVa,b,c ---	93
2		
2	X US,A,3 755 583 (G.G. DE ANGELIS ET AL.) 28 August 1973 see example XIII -----	93

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 00911

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-92, 96, 98-100, 102, 103 are directed to a method of treatment
of (diagnostic method practised on) the human/animal body, the search has
been carried out and based on the alleged effects of the compound/composition.

Further more claims 98-103 have only been searched as far as the activity
of the compounds has been described related to epidermal growth factor
tyrosine Kinase inhibition.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest:

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/00911

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-566226	20-10-93	AU-A- 3101093 CA-A- 2086968 JP-A- 6073025	22-07-93 21-07-93 15-03-94
US-A-3755583	28-08-73	GB-A- 1315901 US-A- 3706747	09-05-73 19-12-72